{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T04:08:56Z","timestamp":1795061336068,"version":"4.10.2"},"reference-count":547,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70114124"],"award-info":[{"award-number":["70114124"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","award":["DKS A2023_01"],"award-info":[{"award-number":["DKS A2023_01"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005687","name":"Goethe-Universit\u00e4t Frankfurt am Main","doi-asserted-by":"publisher","award":["Junior Clinical Scientist programme"],"award-info":[{"award-number":["Junior Clinical Scientist programme"]}],"id":[{"id":"10.13039\/501100005687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00328"],"award-info":[{"award-number":["PI20\/00328"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0E7520N, G081821N and G094522N"],"award-info":[{"award-number":["G0E7520N, G081821N and G094522N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scott-Waudby Trust, Hope Against Cancer Charity","id":[{"id":"https:\/\/ror.org\/02qp25s05","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The B cell lymphoma 2 (BCL2) protein family critically controls apoptosis by regulating the release of cytochrome c from mitochondria. In this cutting-edge review, we summarize the basic biology regulating the BCL2 family including canonical and non-canonical functions, and highlight milestones from basic research to clinical applications in cancer and other pathophysiological conditions. We review laboratory and clinical development of BH3-mimetics as well as more recent approaches including proteolysis targeting chimeras (PROTACs), antibody-drug conjugates (ADCs) and tools targeting the BH4 domain of BCL2. The first BCL2-selective BH3-mimetic, venetoclax, showed remarkable efficacy with manageable toxicities and has transformed the treatment of several hematologic malignancies. Following its success, several chemically similar BCL2 inhibitors such as sonrotoclax and lisaftoclax are currently under clinical evaluation, alone and in combination. Genetic analysis highlights the importance of BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    and MCL1 across different cancer types and the possible utility of BH3-mimetics targeting these proteins. However, the development of BH3-mimetics targeting BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    or MCL1 has been more challenging, with on-target toxicities including thrombocytopenia for BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    and cardiac toxicities for MCL1 inhibitors precluding clinical development. Tumor-specific BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    or MCL1 inhibition may be achieved by novel targeting approaches using PROTACs or selective drug delivery strategies and would be transformational in many subtypes of malignancy. Taken together, we envision that the targeting of BCL2 proteins, while already a success story of translational research, may in the foreseeable future have broader clinical applicability and improve the treatment of multiple diseases.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02176-0","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T20:21:23Z","timestamp":1742502083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":473,"title":["The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2650-586X","authenticated-orcid":false,"given":"Meike","family":"Vogler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike-Andrew","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9863-6538","authenticated-orcid":false,"given":"Raquel S.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja M.","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Callens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Vervliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Macip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5968-4828","authenticated-orcid":false,"given":"Geert","family":"Bultynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin JS","family":"Dyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"2176_CR1","doi-asserted-by":"publisher","first-page":"a041004","DOI":"10.1101\/cshperspect.a041004","volume":"14","author":"DR Green","year":"2022","unstructured":"Green, D. R. A Matter of Life and Death. Cold Spring Harb Perspect Biol. 14, a041004 (2022).","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2176_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh, R., Letai, A. & Sarosiek, K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 20, 175\u2013193 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2176_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cell.2023.11.044","volume":"187","author":"K Newton","year":"2024","unstructured":"Newton, K., Strasser, A., Kayagaki, N. & Dixit, V. M. Cell death. Cell 187, 235\u2013256 (2024).","journal-title":"Cell"},{"key":"2176_CR4","doi-asserted-by":"publisher","first-page":"864874","DOI":"10.3389\/fmolb.2022.864874","volume":"9","author":"V Sora","year":"2022","unstructured":"Sora, V. & Papaleo, E. Structural details of BH3 Motifs and BH3-mediated interactions: an updated perspective. Front Mol. Biosci. 9, 864874 (2022).","journal-title":"Front Mol. Biosci."},{"key":"2176_CR5","doi-asserted-by":"crossref","unstructured":"Banjara, S., Suraweera, C. D., Hinds, M. G. & Kvansakul, M. The Bcl-2 family: ancient origins, conserved structures, and divergent mechanisms. Biomolecules. 10, (2020).","DOI":"10.3390\/biom10010128"},{"key":"2176_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3390\/v9100290","volume":"9","author":"M Kvansakul","year":"2017","unstructured":"Kvansakul, M., Caria, S. & Hinds, M. G. The Bcl-2 family in host-virus interactions. Viruses 9, 290 (2017).","journal-title":"Viruses"},{"key":"2176_CR7","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.6093263","volume":"226","author":"Y Tsujimoto","year":"1984","unstructured":"Tsujimoto, Y. et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226, 1097\u20131099 (1984).","journal-title":"Science"},{"key":"2176_CR8","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1073\/pnas.83.14.5214","volume":"83","author":"Y Tsujimoto","year":"1986","unstructured":"Tsujimoto, Y. & Croce, C. M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl Acad. Sci. Usa. 83, 5214\u20135218 (1986).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"2176_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/315340a0","volume":"315","author":"Y Tsujimoto","year":"1985","unstructured":"Tsujimoto, Y. et al. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 315, 340\u2013343 (1985).","journal-title":"Nature"},{"key":"2176_CR10","first-page":"2133","volume":"9","author":"SL Barrans","year":"2003","unstructured":"Barrans, S. L. et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin. Cancer Res. 9, 2133\u20132139 (2003).","journal-title":"Clin. Cancer Res."},{"key":"2176_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/335440a0","volume":"335","author":"DL Vaux","year":"1988","unstructured":"Vaux, D. L., Cory, S. & Adams, J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335, 440\u2013442 (1988).","journal-title":"Nature"},{"key":"2176_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/0092-8674(93)90509-O","volume":"74","author":"ZN Oltvai","year":"1993","unstructured":"Oltvai, Z. N., Milliman, C. L. & Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609\u2013619 (1993).","journal-title":"Cell"},{"key":"2176_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/381335a0","volume":"381","author":"SW Muchmore","year":"1996","unstructured":"Muchmore, S. W. et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381, 335\u2013341 (1996).","journal-title":"Nature"},{"key":"2176_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.275.5302.983","volume":"275","author":"M Sattler","year":"1997","unstructured":"Sattler, M. et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983\u2013986 (1997).","journal-title":"Science"},{"key":"2176_CR15","first-page":"1921","volume":"11","author":"JM Boyd","year":"1995","unstructured":"Boyd, J. M. et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11, 1921\u20131928 (1995).","journal-title":"Oncogene"},{"key":"2176_CR16","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1101\/gad.10.22.2859","volume":"10","author":"K Wang","year":"1996","unstructured":"Wang, K. et al. BID: a novel BH3 domain-only death agonist. Genes Dev. 10, 2859\u20132869 (1996).","journal-title":"Genes Dev."},{"key":"2176_CR17","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.275.5303.1129","volume":"275","author":"J Yang","year":"1997","unstructured":"Yang, J. et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275, 1129\u20131132 (1997).","journal-title":"Science"},{"key":"2176_CR18","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1126\/science.275.5303.1132","volume":"275","author":"RM Kluck","year":"1997","unstructured":"Kluck, R. M., Bossy-Wetzel, E., Green, D. R. & Newmeyer, D. D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275, 1132\u20131136 (1997).","journal-title":"Science"},{"key":"2176_CR19","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s10495-007-0746-4","volume":"12","author":"B Leber","year":"2007","unstructured":"Leber, B., Lin, J. & Andrews, D. W. Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 12, 897\u2013911 (2007).","journal-title":"Apoptosis"},{"key":"2176_CR20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.molcel.2011.10.001","volume":"44","author":"F Llambi","year":"2011","unstructured":"Llambi, F. et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol. Cell. 44, 517\u2013531 (2011).","journal-title":"Mol. Cell."},{"key":"2176_CR21","doi-asserted-by":"publisher","first-page":"F1000Res","DOI":"10.12688\/f1000research.25607.1","volume":"9","author":"X Luo","year":"2020","unstructured":"Luo, X., O'Neill, K. L. & Huang, K. The third model of Bax\/Bak activation: a Bcl-2 family feud finally resolved?. F1000Res. 9, F1000Res (2020).","journal-title":"F1000Res"},{"key":"2176_CR22","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/cdd.2009.48","volume":"16","author":"M Vogler","year":"2009","unstructured":"Vogler, M. et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 16, 1030\u20131039 (2009).","journal-title":"Cell Death Differ."},{"key":"2176_CR23","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/cdd.2013.79","volume":"20","author":"S Varadarajan","year":"2013","unstructured":"Varadarajan, S. et al. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ. 20, 1475\u20131484 (2013).","journal-title":"Cell Death Differ."},{"key":"2176_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677\u2013681 (2005).","journal-title":"Nature"},{"key":"2176_CR25","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/cdd.2008.31","volume":"15","author":"DL Vaux","year":"2008","unstructured":"Vaux, D. L. ABT-737, proving to be a great tool even before it is proven in the clinic. Cell Death Differ. 15, 807\u2013808 (2008).","journal-title":"Cell Death Differ."},{"key":"2176_CR26","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1126\/science.274.5292.1531","volume":"274","author":"SB Shuker","year":"1996","unstructured":"Shuker, S. B., Hajduk, P. J., Meadows, R. P. & Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531\u20131534 (1996).","journal-title":"Science"},{"key":"2176_CR27","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421\u20133428 (2008).","journal-title":"Cancer Res."},{"key":"2176_CR28","doi-asserted-by":"publisher","first-page":"6902","DOI":"10.1021\/jm800669s","volume":"51","author":"CM Park","year":"2008","unstructured":"Park, C. M. et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med Chem. 51, 6902\u20136915 (2008).","journal-title":"J. Med Chem."},{"key":"2176_CR29","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1074\/jbc.M411434200","volume":"280","author":"CL Day","year":"2005","unstructured":"Day, C. L. et al. Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J. Biol. Chem. 280, 4738\u20134744 (2005).","journal-title":"J. Biol. Chem."},{"key":"2176_CR30","doi-asserted-by":"publisher","first-page":"11024","DOI":"10.1021\/bi000919v","volume":"39","author":"JA Losonczi","year":"2000","unstructured":"Losonczi, J. A. et al. NMR studies of the anti-apoptotic protein Bcl-xL in micelles. Biochemistry 39, 11024\u201311033 (2000).","journal-title":"Biochemistry"},{"key":"2176_CR31","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1073\/pnas.041619798","volume":"98","author":"AM Petros","year":"2001","unstructured":"Petros, A. M. et al. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl Acad. Sci. USA 98, 3012\u20133017 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"2176_CR33","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva, M. et al. Efficacy and biological correlates of response in a Phase II Study of Venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6, 1106\u20131117 (2016).","journal-title":"Cancer Discov."},{"key":"2176_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts, A. W. et al. Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2176_CR35","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer, S. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 17, 768\u2013778 (2016).","journal-title":"Lancet Oncol."},{"key":"2176_CR36","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/0092-8674(93)90508-N","volume":"74","author":"LH Boise","year":"1993","unstructured":"Boise, L. H. et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597\u2013608 (1993).","journal-title":"Cell"},{"key":"2176_CR37","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.4049\/jimmunol.151.4.1979","volume":"151","author":"EY Lin","year":"1993","unstructured":"Lin, E. Y., Orlofsky, A., Berger, M. S. & Prystowsky, M. B. Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J. Immunol. 151, 1979\u20131988 (1993).","journal-title":"J. Immunol."},{"key":"2176_CR38","first-page":"665","volume":"13","author":"L Gibson","year":"1996","unstructured":"Gibson, L. et al. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 13, 665\u2013675 (1996).","journal-title":"Oncogene"},{"key":"2176_CR39","doi-asserted-by":"publisher","first-page":"12481","DOI":"10.1074\/jbc.C000871200","volume":"276","author":"N Ke","year":"2001","unstructured":"Ke, N., Godzik, A. & Reed, J. C. Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak. J. Biol. Chem. 276, 12481\u201312484 (2001).","journal-title":"J. Biol. Chem."},{"key":"2176_CR40","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1182\/blood.V89.2.630","volume":"89","author":"P Zhou","year":"1997","unstructured":"Zhou, P., Qian, L., Kozopas, K. M. & Craig, R. W. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89, 630\u2013643 (1997).","journal-title":"Blood"},{"key":"2176_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1407-6","volume":"10","author":"CFA Warren","year":"2019","unstructured":"Warren, C. F. A., Wong-Brown, M. W. & Bowden, N. A. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 10, 177 (2019).","journal-title":"Cell Death Dis."},{"key":"2176_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bbamcr.2003.08.012","volume":"1644","author":"AM Petros","year":"2004","unstructured":"Petros, A. M., Olejniczak, E. T. & Fesik, S. W. Structural biology of the Bcl-2 family of proteins. Biochim Biophys. Acta 1644, 83\u201394 (2004).","journal-title":"Biochim Biophys. Acta"},{"key":"2176_CR43","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1042\/BCJ20210352","volume":"481","author":"D Nguyen","year":"2024","unstructured":"Nguyen, D., Osterlund, E., Kale, J. & Andrews, D. W. The C-terminal sequences of Bcl-2 family proteins mediate interactions that regulate cell death. Biochem J. 481, 903\u2013922 (2024).","journal-title":"Biochem J."},{"key":"2176_CR44","doi-asserted-by":"publisher","first-page":"30257","DOI":"10.1074\/jbc.M109.040824","volume":"284","author":"G Brien","year":"2009","unstructured":"Brien, G. et al. C-terminal residues regulate localization and function of the antiapoptotic protein Bfl-1. J. Biol. Chem. 284, 30257\u201330263 (2009).","journal-title":"J. Biol. Chem."},{"key":"2176_CR45","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1038\/sj.onc.1201851","volume":"16","author":"C D\u2019Sa-Eipper","year":"1998","unstructured":"D\u2019Sa-Eipper, C. & Chinnadurai, G. Functional dissection of Bfl-1, a Bcl-2 homolog: anti-apoptosis, oncogene-cooperation and cell proliferation activities. Oncogene 16, 3105\u20133114 (1998).","journal-title":"Oncogene"},{"key":"2176_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fcell.2018.00013","volume":"6","author":"N Popgeorgiev","year":"2018","unstructured":"Popgeorgiev, N., Jabbour, L. & Gillet, G. Subcellular localization and dynamics of the Bcl-2 family of proteins. Front Cell Dev. Biol. 6, 13 (2018).","journal-title":"Front Cell Dev. Biol."},{"key":"2176_CR47","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.3390\/ijms22073730","volume":"22","author":"JL Morris","year":"2021","unstructured":"Morris, J. L., Gillet, G., Prudent, J. & Popgeorgiev, N. Bcl-2 Family of Proteins In The Control Of Mitochondrial Calcium Signalling: An Old Chap With New Roles. Int. J. Mol. Sci. 22, 3730 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2176_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2023.102759","volume":"113","author":"N Dhaouadi","year":"2023","unstructured":"Dhaouadi, N. et al. Ca(2+) signaling and cell death. Cell Calcium 113, 102759 (2023).","journal-title":"Cell Calcium"},{"key":"2176_CR49","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.tcb.2018.02.009","volume":"28","author":"G Csordas","year":"2018","unstructured":"Csordas, G., Weaver, D. & Hajnoczky, G. Endoplasmic reticulum-mitochondrial contactology: structure and signaling functions. Trends Cell Biol. 28, 523\u2013540 (2018).","journal-title":"Trends Cell Biol."},{"key":"2176_CR50","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.tcb.2021.02.003","volume":"31","author":"J Loncke","year":"2021","unstructured":"Loncke, J. et al. Balancing ER-Mitochondrial Ca(2+) fluxes in health and disease. Trends Cell Biol. 31, 598\u2013612 (2021).","journal-title":"Trends Cell Biol."},{"key":"2176_CR51","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrm3412","volume":"13","author":"R Rizzuto","year":"2012","unstructured":"Rizzuto, R., De Stefani, D., Raffaello, A. & Mammucari, C. Mitochondria as sensors and regulators of calcium signalling. Nat. Rev. Mol. Cell Biol. 13, 566\u2013578 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2176_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2023.102743","volume":"112","author":"I de Ridder","year":"2023","unstructured":"de Ridder, I. et al. The ER-mitochondria interface, where Ca(2+) and cell death meet. Cell Calcium 112, 102743 (2023).","journal-title":"Cell Calcium"},{"key":"2176_CR53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ceca.2017.05.004","volume":"70","author":"V Giorgio","year":"2018","unstructured":"Giorgio, V. et al. Calcium and regulation of the mitochondrial permeability transition. Cell Calcium 70, 56\u201363 (2018).","journal-title":"Cell Calcium"},{"key":"2176_CR54","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1242\/jcs.00829","volume":"116","author":"MJ Thomenius","year":"2003","unstructured":"Thomenius, M. J. & Distelhorst, C. W. Bcl-2 on the endoplasmic reticulum: protecting the mitochondria from a distance. J. Cell Sci. 116, 4493\u20134499 (2003).","journal-title":"J. Cell Sci."},{"key":"2176_CR55","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1083\/jcb.148.5.857","volume":"148","author":"P Pinton","year":"2000","unstructured":"Pinton, P. et al. Reduced loading of intracellular Ca(2+) stores and downregulation of capacitative Ca(2+) influx in Bcl-2-overexpressing cells. J. Cell Biol. 148, 857\u2013862 (2000).","journal-title":"J. Cell Biol."},{"key":"2176_CR56","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1073\/pnas.97.11.5723","volume":"97","author":"R Foyouzi-Youssefi","year":"2000","unstructured":"Foyouzi-Youssefi, R. et al. Bcl-2 decreases the free Ca2+ concentration within the endoplasmic reticulum. Proc. Natl Acad. Sci. USA 97, 5723\u20135728 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR57","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1093\/emboj\/20.11.2690","volume":"20","author":"P Pinton","year":"2001","unstructured":"Pinton, P. et al. The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. EMBO J. 20, 2690\u20132701 (2001).","journal-title":"EMBO J."},{"key":"2176_CR58","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1083\/jcb.200309146","volume":"166","author":"R Chen","year":"2004","unstructured":"Chen, R. et al. Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate. J. Cell Biol. 166, 193\u2013203 (2004).","journal-title":"J. Cell Biol."},{"key":"2176_CR59","doi-asserted-by":"publisher","first-page":"14397","DOI":"10.1073\/pnas.0907555106","volume":"106","author":"YP Rong","year":"2009","unstructured":"Rong, Y. P. et al. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc. Natl Acad. Sci. USA 106, 14397\u201314402 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR60","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.molcel.2008.06.014","volume":"31","author":"YP Rong","year":"2008","unstructured":"Rong, Y. P. et al. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2\u2019s inhibition of apoptotic calcium signals. Mol. Cell. 31, 255\u2013265 (2008).","journal-title":"Mol. Cell."},{"key":"2176_CR61","doi-asserted-by":"publisher","first-page":"a035089","DOI":"10.1101\/cshperspect.a035089","volume":"12","author":"H Ivanova","year":"2020","unstructured":"Ivanova, H. et al. Bcl-2-protein family as modulators of IP(3) receptors and other organellar Ca(2+) Channels. Cold Spring Harb. Perspect. Biol. 12, a035089 (2020).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2176_CR62","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/ncb1302","volume":"7","author":"C White","year":"2005","unstructured":"White, C. et al. The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the InsP3R. Nat. Cell Biol. 7, 1021\u20131028 (2005).","journal-title":"Nat. Cell Biol."},{"key":"2176_CR63","doi-asserted-by":"publisher","first-page":"12565","DOI":"10.1073\/pnas.0702489104","volume":"104","author":"C Li","year":"2007","unstructured":"Li, C. et al. Apoptosis regulation by Bcl-x(L) modulation of mammalian inositol 1,4,5-trisphosphate receptor channel isoform gating. Proc. Natl Acad. Sci. Usa. 104, 12565\u201312570 (2007).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"2176_CR64","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41418-021-00894-w","volume":"29","author":"N Rosa","year":"2022","unstructured":"Rosa, N. et al. Bcl-xL acts as an inhibitor of IP(3)R channels, thereby antagonizing Ca(2+)-driven apoptosis. Cell Death Differ. 29, 788\u2013805 (2022).","journal-title":"Cell Death Differ."},{"key":"2176_CR65","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41420-024-02112-1","volume":"10","author":"R Gadet","year":"2024","unstructured":"Gadet, R. et al. The endoplasmic reticulum pool of Bcl-xL prevents cell death through IP3R-dependent calcium release. Cell Death Discov. 10, 346 (2024).","journal-title":"Cell Death Discov."},{"key":"2176_CR66","doi-asserted-by":"publisher","first-page":"13678","DOI":"10.1074\/jbc.M109.096040","volume":"285","author":"EF Eckenrode","year":"2010","unstructured":"Eckenrode, E. F. et al. Apoptosis protection by Mcl-1 and Bcl-2 modulation of inositol 1,4,5-trisphosphate receptor-dependent Ca2+ signaling. J. Biol. Chem. 285, 13678\u201313684 (2010).","journal-title":"J. Biol. Chem."},{"key":"2176_CR67","doi-asserted-by":"publisher","first-page":"e19896","DOI":"10.7554\/eLife.19896","volume":"5","author":"B Bonneau","year":"2016","unstructured":"Bonneau, B. et al. IRBIT controls apoptosis by interacting with the Bcl-2 homolog, Bcl2l10, and by promoting ER-mitochondria contact. Elife 5, e19896 (2016).","journal-title":"Elife"},{"key":"2176_CR68","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/0008-5472.CAN-17-0846","volume":"78","author":"A Nougarede","year":"2018","unstructured":"Nougarede, A. et al. Breast cancer targeting through inhibition of the endoplasmic reticulum-based apoptosis regulator Nrh\/BCL2L10. Cancer Res. 78, 1404\u20131417 (2018).","journal-title":"Cancer Res."},{"key":"2176_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05917-7","volume":"14","author":"MQ Duong","year":"2023","unstructured":"Duong, M. Q. et al. Nrh L11R single nucleotide polymorphism, a new prediction biomarker in breast cancer, impacts endoplasmic reticulum-dependent Ca(2+) traffic and response to neoadjuvant chemotherapy. Cell Death Dis. 14, 392 (2023).","journal-title":"Cell Death Dis."},{"key":"2176_CR70","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.neuron.2017.09.034","volume":"96","author":"SE Pease-Raissi","year":"2017","unstructured":"Pease-Raissi, S. E. et al. Paclitaxel reduces axonal Bclw to initiate IP(3)R1-dependent axon degeneration. Neuron 96, 373\u2013386.e376 (2017).","journal-title":"Neuron"},{"key":"2176_CR71","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.chembiol.2024.06.016","volume":"31","author":"SX Tang","year":"2024","unstructured":"Tang, S. X. et al. Dissecting the neuroprotective interaction between the BH4 domain of BCL-w and the IP3 receptor. Cell Chem. Biol. 31, 1815\u20131826.e1815 (2024).","journal-title":"Cell Chem. Biol."},{"key":"2176_CR72","first-page":"2782","volume":"127","author":"T Vervliet","year":"2014","unstructured":"Vervliet, T. et al. Bcl-2 binds to and inhibits ryanodine receptors. J. Cell Sci. 127, 2782\u20132792 (2014).","journal-title":"J. Cell Sci."},{"key":"2176_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/srep09641","volume":"5","author":"T Vervliet","year":"2015","unstructured":"Vervliet, T. et al. Ryanodine receptors are targeted by anti-apoptotic Bcl-XL involving its BH4 domain and Lys87 from its BH3 domain. Sci. Rep. 5, 9641 (2015).","journal-title":"Sci. Rep."},{"key":"2176_CR74","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.bbrc.2015.04.131","volume":"463","author":"T Vervliet","year":"2015","unstructured":"Vervliet, T. et al. Regulation of the ryanodine receptor by anti-apoptotic Bcl-2 is independent of its BH3-domain-binding properties. Biochem Biophys. Res Commun. 463, 174\u2013179 (2015).","journal-title":"Biochem Biophys. Res Commun."},{"key":"2176_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2417-0","volume":"11","author":"ML Hartman","year":"2020","unstructured":"Hartman, M. L. & Czyz, M. BCL-w: apoptotic and non-apoptotic role in health and disease. Cell Death Dis. 11, 260 (2020).","journal-title":"Cell Death Dis."},{"key":"2176_CR76","first-page":"1693","volume":"11","author":"SS Choi","year":"1995","unstructured":"Choi, S. S. et al. A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 11, 1693\u20131698 (1995).","journal-title":"Oncogene"},{"key":"2176_CR77","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/cdd.2011.158","volume":"19","author":"M Vogler","year":"2012","unstructured":"Vogler, M. BCL2A1: the underdog in the BCL2 family. Cell Death Differ. 19, 67\u201374 (2012).","journal-title":"Cell Death Differ."},{"key":"2176_CR78","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1242\/jcs.090514","volume":"125","author":"L Happo","year":"2012","unstructured":"Happo, L., Strasser, A. & Cory, S. BH3-only proteins in apoptosis at a glance. J. Cell Sci. 125, 1081\u20131087 (2012).","journal-title":"J. Cell Sci."},{"key":"2176_CR79","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/cdd.2009.16","volume":"16","author":"J Zhang","year":"2009","unstructured":"Zhang, J. & Ney, P. A. Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ. 16, 939\u2013946 (2009).","journal-title":"Cell Death Differ."},{"key":"2176_CR80","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/sj.cdd.4401934","volume":"14","author":"MG Hinds","year":"2007","unstructured":"Hinds, M. G. et al. BIM, BAD: and BMF: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ. 14, 128\u2013136 (2007).","journal-title":"Cell Death Differ."},{"key":"2176_CR81","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3390\/ijms11041808","volume":"11","author":"GJ Rautureau","year":"2010","unstructured":"Rautureau, G. J., Day, C. L. & Hinds, M. G. Intrinsically disordered proteins in bcl-2 regulated apoptosis. Int J. Mol. Sci. 11, 1808\u20131824 (2010).","journal-title":"Int J. Mol. Sci."},{"key":"2176_CR82","doi-asserted-by":"publisher","first-page":"e21413","DOI":"10.1371\/journal.pone.0021413","volume":"6","author":"S Barrera-Vilarmau","year":"2011","unstructured":"Barrera-Vilarmau, S., Obregon, P. & de Alba, E. Intrinsic order and disorder in the bcl-2 member harakiri: insights into its proapoptotic activity. PLoS One 6, e21413 (2011).","journal-title":"PLoS One"},{"key":"2176_CR83","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/cdd.2013.65","volume":"20","author":"Z Peng","year":"2013","unstructured":"Peng, Z., Xue, B., Kurgan, L. & Uversky, V. N. Resilience of death: intrinsic disorder in proteins involved in the programmed cell death. Cell Death Differ. 20, 1257\u20131267 (2013).","journal-title":"Cell Death Differ."},{"key":"2176_CR84","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0092-8674(00)80572-3","volume":"96","author":"JJ Chou","year":"1999","unstructured":"Chou, J. J. et al. Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell 96, 615\u2013624 (1999).","journal-title":"Cell"},{"key":"2176_CR85","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0092-8674(00)80573-5","volume":"96","author":"JM McDonnell","year":"1999","unstructured":"McDonnell, J. M. et al. Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists. Cell 96, 625\u2013634 (1999).","journal-title":"Cell"},{"key":"2176_CR86","doi-asserted-by":"publisher","first-page":"8704","DOI":"10.1021\/bi901171n","volume":"48","author":"Y Yao","year":"2009","unstructured":"Yao, Y., Bobkov, A. A., Plesniak, L. A. & Marassi, F. M. Mapping the interaction of pro-apoptotic tBID with pro-survival BCL-XL. Biochemistry 48, 8704\u20138711 (2009).","journal-title":"Biochemistry"},{"key":"2176_CR87","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1038\/onc.2009.47","volume":"27","author":"LP Billen","year":"2008","unstructured":"Billen, L. P., Shamas-Din, A. & Andrews, D. W. Bid: a Bax-like BH3 protein. Oncogene 27, S93\u2013S104 (2008).","journal-title":"Oncogene"},{"key":"2176_CR88","doi-asserted-by":"publisher","first-page":"25207","DOI":"10.1074\/jbc.M116.733634","volume":"291","author":"V Andreu-Fernandez","year":"2016","unstructured":"Andreu-Fernandez, V. et al. The C-terminal domains of apoptotic BH3-onLy proteins mediate their insertion into distinct biological membranes. J. Biol. Chem. 291, 25207\u201325216 (2016).","journal-title":"J. Biol. Chem."},{"key":"2176_CR89","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/cdd.2012.9","volume":"19","author":"F Wilfling","year":"2012","unstructured":"Wilfling, F. et al. BH3-only proteins are tail-anchored in the outer mitochondrial membrane and can initiate the activation of Bax. Cell Death Differ. 19, 1328\u20131336 (2012).","journal-title":"Cell Death Differ."},{"key":"2176_CR90","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.bbamcr.2010.11.024","volume":"1813","author":"A Shamas-Din","year":"2011","unstructured":"Shamas-Din, A., Brahmbhatt, H., Leber, B. & Andrews, D. W. BH3-only proteins: Orchestrators of apoptosis. Biochim Biophys. Acta 1813, 508\u2013520 (2011).","journal-title":"Biochim Biophys. Acta"},{"key":"2176_CR91","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo, M. et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 9, 351\u2013365 (2006).","journal-title":"Cancer Cell."},{"key":"2176_CR92","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","volume":"17","author":"L Chen","year":"2005","unstructured":"Chen, L. et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell. 17, 393\u2013403 (2005).","journal-title":"Mol. Cell."},{"key":"2176_CR93","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/nature07396","volume":"455","author":"E Gavathiotis","year":"2008","unstructured":"Gavathiotis, E. et al. BAX activation is initiated at a novel interaction site. Nature 455, 1076\u20131081 (2008).","journal-title":"Nature"},{"key":"2176_CR94","doi-asserted-by":"publisher","first-page":"E986","DOI":"10.1073\/pnas.1214313110","volume":"110","author":"ES Leshchiner","year":"2013","unstructured":"Leshchiner, E. S., Braun, C. R., Bird, G. H. & Walensky, L. D. Direct activation of full-length proapoptotic BAK. Proc. Natl Acad. Sci. USA 110, E986\u2013E995 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR95","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","volume":"2","author":"A Letai","year":"2002","unstructured":"Letai, A. et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2, 183\u2013192 (2002).","journal-title":"Cancer Cell."},{"key":"2176_CR96","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S1097-2765(00)80456-6","volume":"3","author":"H Puthalakath","year":"1999","unstructured":"Puthalakath, H. et al. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol. Cell. 3, 287\u2013296 (1999).","journal-title":"Mol. Cell."},{"key":"2176_CR97","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1126\/science.1062257","volume":"293","author":"H Puthalakath","year":"2001","unstructured":"Puthalakath, H. et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293, 1829\u20131832 (2001).","journal-title":"Science"},{"key":"2176_CR98","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0092-8674(00)00167-7","volume":"103","author":"M Suzuki","year":"2000","unstructured":"Suzuki, M., Youle, R. J. & Tjandra, N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 103, 645\u2013654 (2000).","journal-title":"Cell"},{"key":"2176_CR99","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41580-022-00564-w","volume":"24","author":"P Vandenabeele","year":"2023","unstructured":"Vandenabeele, P., Bultynck, G. & Savvides, S. N. Pore-forming proteins as drivers of membrane permeabilization in cell death pathways. Nat. Rev. Mol. Cell Biol. 24, 312\u2013333 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2176_CR100","doi-asserted-by":"publisher","first-page":"1161910","DOI":"10.3389\/fcell.2023.1161910","volume":"11","author":"CG Bonzerato","year":"2023","unstructured":"Bonzerato, C. G. & Wojcikiewicz, R. J. H. Bok: real killer or bystander with non-apoptotic roles? Front Cell Dev. Biol. 11, 1161910 (2023).","journal-title":"Front Cell Dev. Biol."},{"key":"2176_CR101","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/cdd.2013.10","volume":"20","author":"N Echeverry","year":"2013","unstructured":"Echeverry, N. et al. Intracellular localization of the BCL-2 family member BOK and functional implications. Cell Death Differ. 20, 785\u2013799 (2013).","journal-title":"Cell Death Differ."},{"key":"2176_CR102","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.cell.2016.02.026","volume":"165","author":"F Llambi","year":"2016","unstructured":"Llambi, F. et al. BOK is a non-canonical BCL-2 family effector of apoptosis regulated by ER-associated degradation. Cell 165, 421\u2013433 (2016).","journal-title":"Cell"},{"key":"2176_CR103","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cell.2011.02.034","volume":"145","author":"F Edlich","year":"2011","unstructured":"Edlich, F. et al. Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell 145, 104\u2013116 (2011).","journal-title":"Cell"},{"key":"2176_CR104","doi-asserted-by":"publisher","first-page":"67","DOI":"10.15252\/embj.201488806","volume":"34","author":"F Todt","year":"2015","unstructured":"Todt, F. et al. Differential retrotranslocation of mitochondrial Bax and Bak. EMBO J. 34, 67\u201380 (2015).","journal-title":"EMBO J."},{"key":"2176_CR105","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/febs.14186","volume":"285","author":"A Pena-Blanco","year":"2018","unstructured":"Pena-Blanco, A. & Garcia-Saez, A. J. Bax, Bak and beyond - mitochondrial performance in apoptosis. FEBS J. 285, 416\u2013431 (2018).","journal-title":"FEBS J."},{"key":"2176_CR106","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020107237","volume":"40","author":"JJ Sandow","year":"2021","unstructured":"Sandow, J. J. et al. Dynamic reconfiguration of pro-apoptotic BAK on membranes. EMBO J. 40, e107237 (2021).","journal-title":"EMBO J."},{"key":"2176_CR107","doi-asserted-by":"publisher","first-page":"7629","DOI":"10.1073\/pnas.1702453114","volume":"114","author":"MX Li","year":"2017","unstructured":"Li, M. X. et al. BAK alpha6 permits activation by BH3-only proteins and homooligomerization via the canonical hydrophobic groove. Proc. Natl Acad. Sci. Usa. 114, 7629\u20137634 (2017).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"2176_CR108","doi-asserted-by":"publisher","first-page":"208","DOI":"10.15252\/embj.201591552","volume":"35","author":"Z Zhang","year":"2016","unstructured":"Zhang, Z. et al. BH3-in-groove dimerization initiates and helix 9 dimerization expands Bax pore assembly in membranes. EMBO J. 35, 208\u2013236 (2016).","journal-title":"EMBO J."},{"key":"2176_CR109","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.cell.2012.12.031","volume":"152","author":"PE Czabotar","year":"2013","unstructured":"Czabotar, P. E. et al. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 152, 519\u2013531 (2013).","journal-title":"Cell"},{"key":"2176_CR110","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1074\/jbc.M203392200","volume":"278","author":"V Mikhailov","year":"2003","unstructured":"Mikhailov, V. et al. Association of Bax and Bak homo-oligomers in mitochondria. Bax requirement for Bak reorganization and cytochrome c release. J. Biol. Chem. 278, 5367\u20135376 (2003).","journal-title":"J. Biol. Chem."},{"key":"2176_CR111","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/cdd.2011.138","volume":"19","author":"G Dewson","year":"2012","unstructured":"Dewson, G. et al. Bax dimerizes via a symmetric BH3:groove interface during apoptosis. Cell Death Differ. 19, 661\u2013670 (2012).","journal-title":"Cell Death Differ."},{"key":"2176_CR112","doi-asserted-by":"crossref","unstructured":"Uren, R. T. et al. Disordered clusters of Bak dimers rupture mitochondria during apoptosis. Elife. 6, (2017).","DOI":"10.7554\/eLife.19944"},{"key":"2176_CR113","doi-asserted-by":"publisher","first-page":"20160218","DOI":"10.1098\/rstb.2016.0218","volume":"372","author":"RT Uren","year":"2017","unstructured":"Uren, R. T., Iyer, S. & Kluck, R. M.Pore formation by dimeric Bak and Bax: an unusual pore? Philos. Trans. R. Soc. Lond. B Biol. Sci. 372, 20160218 (2017).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"2176_CR114","doi-asserted-by":"publisher","first-page":"20160217","DOI":"10.1098\/rstb.2016.0217","volume":"372","author":"B Ugarte-Uribe","year":"2017","unstructured":"Ugarte-Uribe, B. & Garcia-Saez, A. J. Apoptotic foci at mitochondria: in and around Bax pores. Philos Trans. R. Soc. Lond. B Biol. Sci 372, 20160217 (2017).","journal-title":"Philos Trans. R. Soc. Lond. B Biol. Sci"},{"key":"2176_CR115","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/s41418-018-0184-6","volume":"25","author":"S Bleicken","year":"2018","unstructured":"Bleicken, S. et al. Topology of active, membrane-embedded Bax in the context of a toroidal pore. Cell Death Differ. 25, 1717\u20131731 (2018).","journal-title":"Cell Death Differ."},{"key":"2176_CR116","doi-asserted-by":"publisher","first-page":"402","DOI":"10.15252\/embj.201592789","volume":"35","author":"L Grosse","year":"2016","unstructured":"Grosse, L. et al. Bax assembles into large ring-like structures remodeling the mitochondrial outer membrane in apoptosis. EMBO J. 35, 402\u2013413 (2016).","journal-title":"EMBO J."},{"key":"2176_CR117","doi-asserted-by":"publisher","first-page":"389","DOI":"10.15252\/embj.201593384","volume":"35","author":"R Salvador-Gallego","year":"2016","unstructured":"Salvador-Gallego, R. et al. Bax assembly into rings and arcs in apoptotic mitochondria is linked to membrane pores. EMBO J. 35, 389\u2013401 (2016).","journal-title":"EMBO J."},{"key":"2176_CR118","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41418-024-01273-x","volume":"31","author":"SV Schweighofer","year":"2024","unstructured":"Schweighofer, S. V. et al. Endogenous BAX and BAK form mosaic rings of variable size and composition on apoptotic mitochondria. Cell Death Differ. 31, 469\u2013478 (2024).","journal-title":"Cell Death Differ."},{"key":"2176_CR119","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1083\/jcb.200610042","volume":"177","author":"S Wasiak","year":"2007","unstructured":"Wasiak, S., Zunino, R. & McBride, H. M. Bax\/Bak promote sumoylation of DRP1 and its stable association with mitochondria during apoptotic cell death. J. Cell Biol. 177, 439\u2013450 (2007).","journal-title":"J. Cell Biol."},{"key":"2176_CR120","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nature05111","volume":"443","author":"M Karbowski","year":"2006","unstructured":"Karbowski, M. et al. Role of Bax and Bak in mitochondrial morphogenesis. Nature 443, 658\u2013662 (2006).","journal-title":"Nature"},{"key":"2176_CR121","doi-asserted-by":"publisher","first-page":"C502","DOI":"10.1152\/ajpcell.00058.2013","volume":"305","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. Altered mitochondrial morphology and defective protein import reveal novel roles for Bax and\/or Bak in skeletal muscle. Am. J. Physiol. Cell Physiol. 305, C502\u2013511 (2013).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2176_CR122","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1083\/jcb.200209124","volume":"159","author":"M Karbowski","year":"2002","unstructured":"Karbowski, M. et al. Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J. Cell Biol. 159, 931\u2013938 (2002).","journal-title":"J. Cell Biol."},{"key":"2176_CR123","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1126\/science.1081208","volume":"300","author":"L Scorrano","year":"2003","unstructured":"Scorrano, L. et al. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 300, 135\u2013139 (2003).","journal-title":"Science"},{"key":"2176_CR124","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1073\/pnas.0408352102","volume":"102","author":"SA Oakes","year":"2005","unstructured":"Oakes, S. A. et al. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc. Natl Acad. Sci. USA 102, 105\u2013110 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR125","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1074\/jbc.M111.275354","volume":"287","author":"G Bultynck","year":"2012","unstructured":"Bultynck, G. et al. The C terminus of Bax inhibitor-1 forms a Ca2+-permeable channel pore. J. Biol. Chem. 287, 2544\u20132557 (2012).","journal-title":"J. Biol. Chem."},{"key":"2176_CR126","doi-asserted-by":"publisher","first-page":"pe22","DOI":"10.1126\/scisignal.2005764","volume":"7","author":"G Bultynck","year":"2014","unstructured":"Bultynck, G., Kiviluoto, S. & Methner, A. Bax inhibitor-1 is likely a pH-sensitive calcium leak channel, not a H+\/Ca2+ exchanger. Sci. Signal. 7, pe22 (2014).","journal-title":"Sci. Signal."},{"key":"2176_CR127","doi-asserted-by":"publisher","first-page":"11477","DOI":"10.1074\/jbc.M708385200","volume":"283","author":"C Xu","year":"2008","unstructured":"Xu, C., Xu, W., Palmer, A. E. & Reed, J. C. BI-1 regulates endoplasmic reticulum Ca2+ homeostasis downstream of Bcl-2 family proteins. J. Biol. Chem. 283, 11477\u201311484 (2008).","journal-title":"J. Biol. Chem."},{"key":"2176_CR128","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.molcel.2015.08.001","volume":"59","author":"J Prudent","year":"2015","unstructured":"Prudent, J. et al. MAPL SUMOylation of Drp1 stabilizes an ER\/Mitochondrial platform required for cell death. Mol. Cell. 59, 941\u2013955 (2015).","journal-title":"Mol. Cell."},{"key":"2176_CR129","doi-asserted-by":"publisher","first-page":"11820","DOI":"10.1074\/jbc.M115.711242","volume":"291","author":"JJ Schulman","year":"2016","unstructured":"Schulman, J. J. et al. The stability and expression level of bok are governed by binding to Inositol 1,4,5-Trisphosphate receptors. J. Biol. Chem. 291, 11820\u201311828 (2016).","journal-title":"J. Biol. Chem."},{"key":"2176_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108827","volume":"34","author":"MA Carpio","year":"2021","unstructured":"Carpio, M. A. et al. BOK controls apoptosis by Ca(2+) transfer through ER-mitochondrial contact sites. Cell Rep. 34, 108827 (2021).","journal-title":"Cell Rep."},{"key":"2176_CR131","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1038\/s41418-019-0327-4","volume":"26","author":"JJ Schulman","year":"2019","unstructured":"Schulman, J. J. et al. Bok regulates mitochondrial fusion and morphology. Cell Death Differ. 26, 2682\u20132694 (2019).","journal-title":"Cell Death Differ."},{"key":"2176_CR132","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0092-8674(93)80065-M","volume":"75","author":"DJ Veis","year":"1993","unstructured":"Veis, D. J., Sorenson, C. M., Shutter, J. R. & Korsmeyer, S. J. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75, 229\u2013240 (1993).","journal-title":"Cell"},{"key":"2176_CR133","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1126\/science.7878471","volume":"267","author":"N Motoyama","year":"1995","unstructured":"Motoyama, N. et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 267, 1506\u20131510 (1995).","journal-title":"Science"},{"key":"2176_CR134","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nature02067","volume":"426","author":"JT Opferman","year":"2003","unstructured":"Opferman, J. T. et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426, 671\u2013676 (2003).","journal-title":"Nature"},{"key":"2176_CR135","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1016\/j.celrep.2018.08.048","volume":"24","author":"S Grabow","year":"2018","unstructured":"Grabow, S. et al. Subtle changes in the levels of BCL-2 proteins cause severe craniofacial abnormalities. Cell Rep. 24, 3285\u20133295.e3284 (2018).","journal-title":"Cell Rep."},{"key":"2176_CR136","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1165\/rcmb.2009-0165OC","volume":"43","author":"RJ Staversky","year":"2010","unstructured":"Staversky, R. J. et al. Epithelial ablation of Bcl-XL increases sensitivity to oxygen without disrupting lung development. Am. J. Respir. Cell Mol. Biol. 43, 376\u2013385 (2010).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2176_CR137","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1038\/cdd.2012.88","volume":"19","author":"T Kodama","year":"2012","unstructured":"Kodama, T. et al. Mcl-1 and Bcl-xL regulate Bak\/Bax-dependent apoptosis of the megakaryocytic lineage at multistages. Cell Death Differ. 19, 1856\u20131869 (2012).","journal-title":"Cell Death Differ."},{"key":"2176_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5539","volume":"5","author":"P Sathe","year":"2014","unstructured":"Sathe, P. et al. Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat. Commun. 5, 4539 (2014).","journal-title":"Nat. Commun."},{"key":"2176_CR139","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrc.2015.17","volume":"16","author":"AR Delbridge","year":"2016","unstructured":"Delbridge, A. R., Grabow, S., Strasser, A. & Vaux, D. L. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat. Rev. Cancer 16, 99\u2013109 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"2176_CR140","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1182\/blood-2017-03-771576","volume":"130","author":"R Jain","year":"2017","unstructured":"Jain, R. et al. A critical epithelial survival axis regulated by MCL-1 maintains thymic function in mice. Blood 130, 2504\u20132515 (2017).","journal-title":"Blood"},{"key":"2176_CR141","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1053\/j.gastro.2020.03.017","volume":"159","author":"ME Healy","year":"2020","unstructured":"Healy, M. E. et al. MCL1 is required for maintenance of intestinal homeostasis and prevention of carcinogenesis in mice. Gastroenterology 159, 183\u2013199 (2020).","journal-title":"Gastroenterology"},{"key":"2176_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2021.118997","volume":"1868","author":"M Callens","year":"2021","unstructured":"Callens, M. et al. The role of Bcl-2 proteins in modulating neuronal Ca(2+) signaling in health and in Alzheimer\u2019s disease. Biochim Biophys. Acta Mol. Cell Res. 1868, 118997 (2021).","journal-title":"Biochim Biophys. Acta Mol. Cell Res."},{"key":"2176_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33836-2","volume":"13","author":"F Zhao","year":"2022","unstructured":"Zhao, F. et al. Brain milieu induces early microglial maturation through the BAX-Notch axis. Nat. Commun. 13, 6117 (2022).","journal-title":"Nat. Commun."},{"key":"2176_CR144","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ng0398-251","volume":"18","author":"AJ Ross","year":"1998","unstructured":"Ross, A. J. et al. Testicular degeneration in Bclw-deficient mice. Nat. Genet. 18, 251\u2013256 (1998).","journal-title":"Nat. Genet."},{"key":"2176_CR145","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1095\/biolreprod65.1.318","volume":"65","author":"LD Russell","year":"2001","unstructured":"Russell, L. D. et al. Spermatogenesis in Bclw-deficient mice. Biol. Reprod. 65, 318\u2013332 (2001).","journal-title":"Biol. Reprod."},{"key":"2176_CR146","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1172\/JCI89486","volume":"127","author":"CM Adams","year":"2017","unstructured":"Adams, C. M. et al. BCL-W has a fundamental role in B cell survival and lymphomagenesis. J. Clin. Invest. 127, 635\u2013650 (2017).","journal-title":"J. Clin. Invest."},{"key":"2176_CR147","doi-asserted-by":"publisher","first-page":"6032","DOI":"10.1182\/blood-2011-12-399089","volume":"119","author":"E Ottina","year":"2012","unstructured":"Ottina, E. et al. Targeting antiapoptotic A1\/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice. Blood 119, 6032\u20136042 (2012).","journal-title":"Blood"},{"key":"2176_CR148","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.4049\/jimmunol.1400637","volume":"194","author":"E Ottina","year":"2015","unstructured":"Ottina, E. et al. Knockdown of the antiapoptotic Bcl-2 family member A1\/Bfl-1 protects mice from anaphylaxis. J. Immunol. 194, 1316\u20131322 (2015).","journal-title":"J. Immunol."},{"key":"2176_CR149","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/cdd.2016.156","volume":"24","author":"RL Schenk","year":"2017","unstructured":"Schenk, R. L. et al. Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment. Cell Death Differ. 24, 534\u2013545 (2017).","journal-title":"Cell Death Differ."},{"key":"2176_CR150","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/cdd.2016.155","volume":"24","author":"S Tuzlak","year":"2017","unstructured":"Tuzlak, S. et al. The BCL-2 pro-survival protein A1 is dispensable for T cell homeostasis on viral infection. Cell Death Differ. 24, 523\u2013533 (2017).","journal-title":"Cell Death Differ."},{"key":"2176_CR151","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1126\/science.270.5233.96","volume":"270","author":"CM Knudson","year":"1995","unstructured":"Knudson, C. M. et al. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270, 96\u201399 (1995).","journal-title":"Science"},{"key":"2176_CR152","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1097-2765(00)00136-2","volume":"6","author":"T Lindsten","year":"2000","unstructured":"Lindsten, T. et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol. Cell. 6, 1389\u20131399 (2000).","journal-title":"Mol. Cell."},{"key":"2176_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.304","volume":"6","author":"F Ke","year":"2015","unstructured":"Ke, F. et al. Impact of the combined loss of BOK, BAX and BAK on the hematopoietic system is slightly more severe than compound loss of BAX and BAK. Cell Death Dis. 6, e1938 (2015).","journal-title":"Cell Death Dis."},{"key":"2176_CR154","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/cdd.2017.84","volume":"24","author":"S Arakawa","year":"2017","unstructured":"Arakawa, S. et al. Role of Atg5-dependent cell death in the embryonic development of Bax\/Bak double-knockout mice. Cell Death Differ. 24, 1598\u20131608 (2017).","journal-title":"Cell Death Differ."},{"key":"2176_CR155","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/ncb1192","volume":"6","author":"S Shimizu","year":"2004","unstructured":"Shimizu, S. et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat. Cell Biol. 6, 1221\u20131228 (2004).","journal-title":"Nat. Cell Biol."},{"key":"2176_CR156","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1126\/science.286.5445.1735","volume":"286","author":"P Bouillet","year":"1999","unstructured":"Bouillet, P. et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286, 1735\u20131738 (1999).","journal-title":"Science"},{"key":"2176_CR157","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1535-6108(03)00244-7","volume":"4","author":"JR Jeffers","year":"2003","unstructured":"Jeffers, J. R. et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 4, 321\u2013328 (2003).","journal-title":"Cancer Cell."},{"key":"2176_CR158","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1101\/gad.1103603","volume":"17","author":"T Shibue","year":"2003","unstructured":"Shibue, T. et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev. 17, 2233\u20132238 (2003).","journal-title":"Genes Dev."},{"key":"2176_CR159","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1126\/science.1090072","volume":"302","author":"A Villunger","year":"2003","unstructured":"Villunger, A. et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302, 1036\u20131038 (2003).","journal-title":"Science"},{"key":"2176_CR160","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2012.05.030","volume":"37","author":"DH Gray","year":"2012","unstructured":"Gray, D. H. et al. The BH3-only proteins Bim and Puma cooperate to impose deletional tolerance of organ-specific antigens. Immunity 37, 451\u2013462 (2012).","journal-title":"Immunity"},{"key":"2176_CR161","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1182\/blood-2013-11-537217","volume":"123","author":"V Labi","year":"2014","unstructured":"Labi, V. et al. Deregulated cell death and lymphocyte homeostasis cause premature lethality in mice lacking the BH3-only proteins BIM and BMF. Blood 123, 2652\u20132662 (2014).","journal-title":"Blood"},{"key":"2176_CR162","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1084\/jem.20061552","volume":"203","author":"M Erlacher","year":"2006","unstructured":"Erlacher, M. et al. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J. Exp. Med. 203, 2939\u20132951 (2006).","journal-title":"J. Exp. Med."},{"key":"2176_CR163","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1126\/science.1190217","volume":"330","author":"D Ren","year":"2010","unstructured":"Ren, D. et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 330, 1390\u20131393 (2010).","journal-title":"Science"},{"key":"2176_CR164","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/cdd.2017.169","volume":"25","author":"BJ Aubrey","year":"2018","unstructured":"Aubrey, B. J. et al. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 25, 104\u2013113 (2018).","journal-title":"Cell Death Differ."},{"key":"2176_CR165","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/ijms19010308","volume":"19","author":"J Cui","year":"2018","unstructured":"Cui, J. & Placzek, W. J. Post-Transcriptional Regulation of Anti-Apoptotic BCL2 Family Members. Int. J. Mol. Sci. 19, 308 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2176_CR166","doi-asserted-by":"publisher","first-page":"119047","DOI":"10.1016\/j.bbamcr.2021.119047","volume":"1868","author":"G Prado","year":"2021","unstructured":"Prado, G., Kaestner, C. L., Licht, J. D. & Bennett, R. L. Targeting epigenetic mechanisms to overcome venetoclax resistance. Biochim Biophys. Acta Mol. Cell Res. 1868, 119047 (2021).","journal-title":"Biochim Biophys. Acta Mol. Cell Res."},{"key":"2176_CR167","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0081-z","volume":"5","author":"W Zhang","year":"2017","unstructured":"Zhang, W. & Xu, J. DNA methyltransferases and their roles in tumorigenesis. Biomark. Res. 5, 1 (2017).","journal-title":"Biomark. Res."},{"key":"2176_CR168","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1080\/15592294.2016.1237345","volume":"11","author":"I Schiffmann","year":"2016","unstructured":"Schiffmann, I., Greve, G., Jung, M. & Lubbert, M. Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. Epigenetics 11, 858\u2013870 (2016).","journal-title":"Epigenetics"},{"key":"2176_CR169","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.clml.2018.02.005","volume":"18","author":"R El Fakih","year":"2018","unstructured":"El Fakih, R. et al. Azacitidine Use for Myeloid Neoplasms. Clin. Lymphoma Myeloma Leuk. 18, e147\u2013e155 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2176_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian, H. et al. Current status and research directions in acute myeloid leukemia. Blood Cancer J. 14, 163 (2024).","journal-title":"Blood Cancer J."},{"key":"2176_CR171","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03144-y","volume":"11","author":"I Kapoor","year":"2020","unstructured":"Kapoor, I. et al. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis. 11, 941 (2020).","journal-title":"Cell Death Dis."},{"key":"2176_CR172","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel, J. F. et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 15, 1195\u20131206 (2014).","journal-title":"Lancet Oncol."},{"key":"2176_CR173","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood.2021014304","volume":"140","author":"D Thomalla","year":"2022","unstructured":"Thomalla, D. et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood 140, 2113\u20132126 (2022).","journal-title":"Blood"},{"key":"2176_CR174","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1136\/gut.2009.180711","volume":"58","author":"P Fritsche","year":"2009","unstructured":"Fritsche, P. et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 58, 1399\u20131409 (2009).","journal-title":"Gut"},{"key":"2176_CR175","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/15384047.2015.1108485","volume":"17","author":"W Nakajima","year":"2016","unstructured":"Nakajima, W. et al. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer. Cancer Biol. Ther. 17, 27\u201335 (2016).","journal-title":"Cancer Biol. Ther."},{"key":"2176_CR176","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-16-2622","volume":"23","author":"AM Torres-Adorno","year":"2017","unstructured":"Torres-Adorno, A. M. et al. Histone deacetylase inhibitor enhances the efficacy of MEK inhibitor through NOXA-mediated MCL1 degradation in triple-negative and inflammatory breast cancer. Clin. Cancer Res. 23, 4780\u20134792 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2176_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.9","volume":"4","author":"JE Bolden","year":"2013","unstructured":"Bolden, J. E. et al. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis. 4, e519 (2013).","journal-title":"Cell Death Dis."},{"key":"2176_CR178","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-018-0605-x","volume":"11","author":"C He","year":"2019","unstructured":"He, C. et al. Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin. Clin. Epigenet. 11, 8 (2019).","journal-title":"Clin. Epigenet."},{"key":"2176_CR179","doi-asserted-by":"publisher","first-page":"102148","DOI":"10.1016\/j.cbpa.2022.102148","volume":"68","author":"MP Schwalm","year":"2022","unstructured":"Schwalm, M. P. & Knapp, S. BET bromodomain inhibitors. Curr. Opin. Chem. Biol. 68, 102148 (2022).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"2176_CR180","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1182\/bloodadvances.2020002231","volume":"4","author":"TEC Cummin","year":"2020","unstructured":"Cummin, T. E. C. et al. BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. Blood Adv. 4, 3316\u20133328 (2020).","journal-title":"Blood Adv."},{"key":"2176_CR181","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-15-0924","volume":"15","author":"SJ Hogg","year":"2016","unstructured":"Hogg, S. J. et al. BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members. Mol. Cancer Ther. 15, 2030\u20132041 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"2176_CR182","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1002\/ijc.33000","volume":"147","author":"HY Tseng","year":"2020","unstructured":"Tseng, H. Y. et al. Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma. Int J. Cancer 147, 2176\u20132189 (2020).","journal-title":"Int J. Cancer"},{"key":"2176_CR183","doi-asserted-by":"publisher","first-page":"18698","DOI":"10.1074\/jbc.RA119.010176","volume":"294","author":"SP O\u2019Hara","year":"2019","unstructured":"O\u2019Hara, S. P. et al. The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1. J. Biol. Chem. 294, 18698\u201318713 (2019).","journal-title":"J. Biol. Chem."},{"key":"2176_CR184","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00001622-200011000-00006","volume":"12","author":"JM Grad","year":"2000","unstructured":"Grad, J. M., Zeng, X. R. & Boise, L. H. Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Curr. Opin. Oncol. 12, 543\u2013549 (2000).","journal-title":"Curr. Opin. Oncol."},{"key":"2176_CR185","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01782-9","volume":"22","author":"NM Pieper","year":"2024","unstructured":"Pieper, N. M. et al. Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFkappaB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell Commun. Signal. 22, 415 (2024).","journal-title":"Cell Commun. Signal."},{"key":"2176_CR186","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","volume":"27","author":"VV Senichkin","year":"2020","unstructured":"Senichkin, V. V. et al. Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 27, 405\u2013419 (2020).","journal-title":"Cell Death Differ."},{"key":"2176_CR187","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/s41418-020-00692-w","volume":"28","author":"M Haselager","year":"2021","unstructured":"Haselager, M. et al. Regulation of Bcl-XL by non-canonical NF-kappaB in the context of CD40-induced drug resistance in CLL. Cell Death Differ. 28, 1658\u20131668 (2021).","journal-title":"Cell Death Differ."},{"key":"2176_CR188","doi-asserted-by":"publisher","first-page":"9136","DOI":"10.1073\/pnas.96.16.9136","volume":"96","author":"HH Lee","year":"1999","unstructured":"Lee, H. H. et al. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1\/A1 is required for CD40 survival signaling in B lymphocytes. Proc. Natl Acad. Sci. USA 96, 9136\u20139141 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR189","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1038\/onc.2008.24","volume":"27","author":"Z Fu","year":"2008","unstructured":"Fu, Z. & Tindall, D. J. FOXOs, cancer and regulation of apoptosis. Oncogene 27, 2312\u20132319 (2008).","journal-title":"Oncogene"},{"key":"2176_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109453","volume":"114","author":"L Li","year":"2023","unstructured":"Li, L. et al. Sevoflurane protects against intracerebral hemorrhage via microRNA-133b\/FOXO4\/BCL2 axis. Int. Immunopharmacol. 114, 109453 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"2176_CR191","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/neuonc\/nor119","volume":"13","author":"BW Day","year":"2011","unstructured":"Day, B. W. et al. ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1. Neuro Oncol. 13, 1202\u20131212 (2011).","journal-title":"Neuro Oncol."},{"key":"2176_CR192","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1182\/blood-2011-07-366492","volume":"119","author":"J Hu","year":"2012","unstructured":"Hu, J. et al. Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition. Blood 119, 826\u2013837 (2012).","journal-title":"Blood"},{"key":"2176_CR193","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/jcb.20683","volume":"97","author":"XH Liu","year":"2006","unstructured":"Liu, X. H., Yu, E. Z., Li, Y. Y. & Kagan, E. HIF-1alpha has an anti-apoptotic effect in human airway epithelium that is mediated via Mcl-1 gene expression. J. Cell Biochem. 97, 755\u2013765 (2006).","journal-title":"J. Cell Biochem."},{"key":"2176_CR194","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/sj.onc.1205157","volume":"21","author":"R Croxton","year":"2002","unstructured":"Croxton, R. et al. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 21, 1359\u20131369 (2002).","journal-title":"Oncogene"},{"key":"2176_CR195","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/cas.12160","volume":"104","author":"H Tagawa","year":"2013","unstructured":"Tagawa, H., Ikeda, S. & Sawada, K. Role of microRNA in the pathogenesis of malignant lymphoma. Cancer Sci. 104, 801\u2013809 (2013).","journal-title":"Cancer Sci."},{"key":"2176_CR196","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/pros.1131","volume":"49","author":"JT Dong","year":"2001","unstructured":"Dong, J. T., Boyd, J. C. & Frierson, H. F. Jr Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer. Prostate 49, 166\u2013171 (2001).","journal-title":"Prostate"},{"key":"2176_CR197","doi-asserted-by":"publisher","first-page":"15524","DOI":"10.1073\/pnas.242606799","volume":"99","author":"GA Calin","year":"2002","unstructured":"Calin, G. A. et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99, 15524\u201315529 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR198","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/jcp.20282","volume":"204","author":"A Bottoni","year":"2005","unstructured":"Bottoni, A. et al. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J. Cell Physiol. 204, 280\u2013285 (2005).","journal-title":"J. Cell Physiol."},{"key":"2176_CR199","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.0506654102","volume":"102","author":"A Cimmino","year":"2005","unstructured":"Cimmino, A. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102, 13944\u201313949 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR200","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/nm.1880","volume":"14","author":"D Bonci","year":"2008","unstructured":"Bonci, D. et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 14, 1271\u20131277 (2008).","journal-title":"Nat. Med."},{"key":"2176_CR201","first-page":"104","volume":"28","author":"ZH Li","year":"2020","unstructured":"Li, Z. H., Zhang, Y. P., Xing, P. T. & Zhan, X. R. Effect of MiRNA-145 on APOPTOSIS OF LEUKemia HuT 78 CELLS AND ITS MEChanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 28, 104\u2013109 (2020).","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi."},{"key":"2176_CR202","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/978-1-4939-3378-5_21","volume":"1402","author":"MD Paraskevopoulou","year":"2016","unstructured":"Paraskevopoulou, M. D. & Hatzigeorgiou, A. G. Analyzing MiRNA-LncRNA Interactions. Methods Mol. Biol. 1402, 271\u2013286 (2016).","journal-title":"Methods Mol. Biol."},{"key":"2176_CR203","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1042\/BST0381571","volume":"38","author":"S Willimott","year":"2010","unstructured":"Willimott, S. & Wagner, S. D. Post-transcriptional and post-translational regulation of Bcl2. Biochem. Soc. Trans. 38, 1571\u20131575 (2010).","journal-title":"Biochem. Soc. Trans."},{"key":"2176_CR204","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/1541-7786.MCR-10-0325","volume":"9","author":"N Filippova","year":"2011","unstructured":"Filippova, N. et al. The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol. Cancer Res. 9, 648\u2013659 (2011).","journal-title":"Mol. Cancer Res."},{"key":"2176_CR205","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627922","volume":"12","author":"E Dobosz","year":"2021","unstructured":"Dobosz, E. et al. MCPIP-1 restricts inflammation via promoting apoptosis of neutrophils. Front Immunol. 12, 627922 (2021).","journal-title":"Front Immunol."},{"key":"2176_CR206","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/cmi.2016.70","volume":"14","author":"R Mao","year":"2017","unstructured":"Mao, R. et al. Regnase-1, a rapid response ribonuclease regulating inflammation and stress responses. Cell Mol. Immunol. 14, 412\u2013422 (2017).","journal-title":"Cell Mol. Immunol."},{"key":"2176_CR207","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.cdd.4400998","volume":"9","author":"H Puthalakath","year":"2002","unstructured":"Puthalakath, H. & Strasser, A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 9, 505\u2013512 (2002).","journal-title":"Cell Death Differ."},{"key":"2176_CR208","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","volume":"7","author":"K Nakano","year":"2001","unstructured":"Nakano, K. & Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell. 7, 683\u2013694 (2001).","journal-title":"Mol. Cell."},{"key":"2176_CR209","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1016\/j.febslet.2006.08.088","volume":"580","author":"PJ Real","year":"2006","unstructured":"Real, P. J. et al. Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells. FEBS Lett. 580, 5905\u20135909 (2006).","journal-title":"FEBS Lett."},{"key":"2176_CR210","doi-asserted-by":"publisher","first-page":"10486","DOI":"10.1128\/JVI.00808-07","volume":"81","author":"T Subramanian","year":"2007","unstructured":"Subramanian, T. et al. Evidence for involvement of BH3-only proapoptotic members in adenovirus-induced apoptosis. J. Virol. 81, 10486\u201310495 (2007).","journal-title":"J. Virol."},{"key":"2176_CR211","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1084\/jem.20030613","volume":"199","author":"JY Kim","year":"2004","unstructured":"Kim, J. Y. et al. BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha. J. Exp. Med. 199, 113\u2013124 (2004).","journal-title":"J. Exp. Med."},{"key":"2176_CR212","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S0960-9822(00)00728-4","volume":"10","author":"PF Dijkers","year":"2000","unstructured":"Dijkers, P. F. et al. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. 10, 1201\u20131204 (2000).","journal-title":"Curr. Biol."},{"key":"2176_CR213","doi-asserted-by":"publisher","first-page":"49795","DOI":"10.1074\/jbc.M309523200","volume":"278","author":"A Sunters","year":"2003","unstructured":"Sunters, A. et al. FoxO3a transcriptional regulation of BIM controls apoptosis in paclitaxel-treated breast cancer cell lines. J. Biol. Chem. 278, 49795\u201349805 (2003).","journal-title":"J. Biol. Chem."},{"key":"2176_CR214","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1084\/jem.20060353","volume":"203","author":"H You","year":"2006","unstructured":"You, H. et al. FOXO3a-dependent regulation of Puma in response to cytokine\/growth factor withdrawal. J. Exp. Med. 203, 1657\u20131663 (2006).","journal-title":"J. Exp. Med."},{"key":"2176_CR215","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1074\/jbc.M112.386102","volume":"288","author":"R Gogada","year":"2013","unstructured":"Gogada, R. et al. Bim, a proapoptotic protein, up-regulated via transcription factor E2F1-dependent mechanism, functions as a prosurvival molecule in cancer. J. Biol. Chem. 288, 368\u2013381 (2013).","journal-title":"J. Biol. Chem."},{"key":"2176_CR216","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s10495-023-01924-3","volume":"29","author":"Y Hu","year":"2024","unstructured":"Hu, Y. et al. Acetylation of FOXO1 activates BIM expression involved in CVB3 induced cardiomyocyte apoptosis. Apoptosis 29, 1271\u20131287 (2024).","journal-title":"Apoptosis"},{"key":"2176_CR217","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/s41375-020-01078-0","volume":"35","author":"PL Fedele","year":"2021","unstructured":"Fedele, P. L. et al. The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival. Leukemia 35, 2114\u20132118 (2021).","journal-title":"Leukemia"},{"key":"2176_CR218","doi-asserted-by":"publisher","first-page":"e20230183","DOI":"10.1084\/jem.20230183","volume":"220","author":"PJ Titcombe","year":"2023","unstructured":"Titcombe, P. J., Silva Morales, M., Zhang, N. & Mueller, D. L. BATF represses BIM to sustain tolerant T cells in the periphery. J. Exp. Med. 220, e20230183 (2023).","journal-title":"J. Exp. Med."},{"key":"2176_CR219","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.bbrc.2020.03.139","volume":"526","author":"A Inoue-Yamauchi","year":"2020","unstructured":"Inoue-Yamauchi, A. & Oda, H. EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2\/BCL-X(L) inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells. Biochem. Biophys. Res. Commun. 526, 612\u2013617 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2176_CR220","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1093\/emboj\/20.9.2286","volume":"20","author":"C Sanz","year":"2001","unstructured":"Sanz, C. et al. Interleukin 3-dependent activation of DREAM is involved in transcriptional silencing of the apoptotic Hrk gene in hematopoietic progenitor cells. EMBO J. 20, 2286\u20132292 (2001).","journal-title":"EMBO J."},{"key":"2176_CR221","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1084\/jem.20072000","volume":"205","author":"M Yamashita","year":"2008","unstructured":"Yamashita, M. et al. Bmi1 regulates memory CD4 T cell survival via repression of the Noxa gene. J. Exp. Med. 205, 1109\u20131120 (2008).","journal-title":"J. Exp. Med."},{"key":"2176_CR222","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.molcel.2006.12.007","volume":"25","author":"H Matsui","year":"2007","unstructured":"Matsui, H., Asou, H. & Inaba, T. Cytokines direct the regulation of Bim mRNA stability by heat-shock cognate protein 70. Mol. Cell. 25, 99\u2013112 (2007).","journal-title":"Mol. Cell."},{"key":"2176_CR223","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/ni1575","volume":"9","author":"C Xiao","year":"2008","unstructured":"Xiao, C. et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 9, 405\u2013414 (2008).","journal-title":"Nat. Immunol."},{"key":"2176_CR224","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ccr.2014.06.014","volume":"26","author":"Y Li","year":"2014","unstructured":"Li, Y. et al. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell. 26, 262\u2013272 (2014).","journal-title":"Cancer Cell."},{"key":"2176_CR225","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1038\/sj.leu.2403942","volume":"19","author":"H Tagawa","year":"2005","unstructured":"Tagawa, H. & Seto, M. A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia 19, 2013\u20132016 (2005).","journal-title":"Leukemia"},{"key":"2176_CR226","doi-asserted-by":"publisher","first-page":"7229","DOI":"10.1002\/jcb.27997","volume":"120","author":"Z Lu","year":"2019","unstructured":"Lu, Z., Luo, M. & Huang, Y. lncRNA-CIR regulates cell apoptosis of chondrocytes in osteoarthritis. J. Cell Biochem. 120, 7229\u20137237 (2019).","journal-title":"J. Cell Biochem."},{"key":"2176_CR227","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107816","volume":"31","author":"Z Cai","year":"2020","unstructured":"Cai, Z. et al. Targeting BIM via a lncRNA Morrbid regulates the survival of preleukemic and leukemic cells. Cell Rep. 31, 107816 (2020).","journal-title":"Cell Rep."},{"key":"2176_CR228","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature19346","volume":"537","author":"JJ Kotzin","year":"2016","unstructured":"Kotzin, J. J. et al. The long non-coding RNA Morrbid regulates Bim and short-lived myeloid cell lifespan. Nature 537, 239\u2013243 (2016).","journal-title":"Nature"},{"key":"2176_CR229","doi-asserted-by":"publisher","first-page":"12537","DOI":"10.18632\/aging.202927","volume":"13","author":"Q Wang","year":"2021","unstructured":"Wang, Q. et al. Silencing long noncoding RNA NEAT1 alleviates acute liver failure via the EZH2-mediated microRNA-139\/PUMA axis. Aging. 13, 12537\u201312551 (2021).","journal-title":"Aging."},{"key":"2176_CR230","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1080\/15384101.2020.1843773","volume":"19","author":"Z Du","year":"2020","unstructured":"Du, Z. et al. The long non-coding RNA TSLC8 inhibits colorectal cancer by stabilizing puma. Cell Cycle 19, 3317\u20133328 (2020).","journal-title":"Cell Cycle"},{"key":"2176_CR231","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-229","volume":"9","author":"CZ Zhang","year":"2010","unstructured":"Zhang, C. Z. et al. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol. Cancer 9, 229 (2010).","journal-title":"Mol. Cancer"},{"key":"2176_CR232","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/01616412.2019.1672382","volume":"42","author":"XB Zhou","year":"2020","unstructured":"Zhou, X. B. et al. LncRNAGAS5 sponges miRNA-221 to promote neurons apoptosis by up-regulated PUMA under hypoxia condition. Neurol. Res. 42, 8\u201316 (2020).","journal-title":"Neurol. Res."},{"key":"2176_CR233","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.3892\/mmr.2016.4863","volume":"13","author":"H Sun","year":"2016","unstructured":"Sun, H. et al. MicroRNA\u201121 expression is associated with the clinical features of patients with gastric carcinoma and affects the proliferation, invasion and migration of gastric cancer cells by regulating Noxa. Mol. Med Rep. 13, 2701\u20132707 (2016).","journal-title":"Mol. Med Rep."},{"key":"2176_CR234","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57099-7","volume":"14","author":"J Shi","year":"2024","unstructured":"Shi, J. et al. Noxa inhibits oncogenesis through ZNF519 in gastric cancer and is suppressed by hsa-miR-200b-3p. Sci. Rep. 14, 6568 (2024).","journal-title":"Sci. Rep."},{"key":"2176_CR235","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/cdd.2014.6","volume":"21","author":"ME Fiori","year":"2014","unstructured":"Fiori, M. E. et al. Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ. 21, 774\u2013782 (2014).","journal-title":"Cell Death Differ."},{"key":"2176_CR236","doi-asserted-by":"publisher","first-page":"11443","DOI":"10.1074\/jbc.M114.625988","volume":"290","author":"TM Morey","year":"2015","unstructured":"Morey, T. M. et al. Heat shock inhibition of CDK5 increases NOXA levels through miR-23a repression. J. Biol. Chem. 290, 11443\u201311454 (2015).","journal-title":"J. Biol. Chem."},{"key":"2176_CR237","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.biopha.2017.09.087","volume":"95","author":"Z Wu","year":"2017","unstructured":"Wu, Z. et al. The BET-Bromodomain Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression. Biomed. Pharmacother. 95, 1574\u20131579 (2017).","journal-title":"Biomed. Pharmacother."},{"key":"2176_CR238","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/onc.2013.177","volume":"33","author":"K Teshima","year":"2014","unstructured":"Teshima, K. et al. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma. Oncogene 33, 2191\u20132203 (2014).","journal-title":"Oncogene"},{"key":"2176_CR239","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.3390\/ijms15033746","volume":"15","author":"MA Westhoff","year":"2014","unstructured":"Westhoff, M. A. et al. Killing me softly-future challenges in apoptosis research. Int J. Mol. Sci. 15, 3746\u20133767 (2014).","journal-title":"Int J. Mol. Sci."},{"key":"2176_CR240","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","volume":"91","author":"SR Datta","year":"1997","unstructured":"Datta, S. R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231\u2013241 (1997).","journal-title":"Cell"},{"key":"2176_CR241","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1126\/science.278.5338.687","volume":"278","author":"L del Peso","year":"1997","unstructured":"del Peso, L. et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687\u2013689 (1997).","journal-title":"Science"},{"key":"2176_CR242","doi-asserted-by":"publisher","first-page":"21085","DOI":"10.1074\/jbc.M400063200","volume":"279","author":"SJ Gardai","year":"2004","unstructured":"Gardai, S. J. et al. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J. Biol. Chem. 279, 21085\u201321095 (2004).","journal-title":"J. Biol. Chem."},{"key":"2176_CR243","doi-asserted-by":"publisher","first-page":"e45235","DOI":"10.15252\/embr.201745235","volume":"19","author":"J Kale","year":"2018","unstructured":"Kale, J. et al. Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Rep. 19, e45235 (2018).","journal-title":"EMBO Rep."},{"key":"2176_CR244","doi-asserted-by":"publisher","first-page":"22989","DOI":"10.3390\/ijms160922989","volume":"16","author":"H Guo","year":"2015","unstructured":"Guo, H. et al. Modulation of the PI3K\/Akt pathway and Bcl-2 family proteins involved in chicken's tubular apoptosis induced by Nickel Chloride (NiCl(2). Int. J. Mol. Sci. 16, 22989\u201323011 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"2176_CR245","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.18632\/oncotarget.13817","volume":"8","author":"Y Dai","year":"2017","unstructured":"Dai, Y., Jin, S., Li, X. & Wang, D. The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer. Oncotarget 8, 1354\u20131368 (2017).","journal-title":"Oncotarget"},{"key":"2176_CR246","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1038\/onc.2009.42","volume":"27","author":"JD Pinon","year":"2008","unstructured":"Pinon, J. D., Labi, V., Egle, A. & Villunger, A. BIM and BMF in tissue homeostasis and malignant disease. Oncogene 27, S41\u2013S52 (2008).","journal-title":"Oncogene"},{"key":"2176_CR247","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1073\/pnas.0438011100","volume":"100","author":"K Lei","year":"2003","unstructured":"Lei, K. & Davis, R. J. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc. Natl Acad. Sci. USA 100, 2432\u20132437 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR248","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1038\/sj.emboj.7601723","volume":"26","author":"KE Ewings","year":"2007","unstructured":"Ewings, K. E. et al. ERK1\/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J. 26, 2856\u20132867 (2007).","journal-title":"EMBO J."},{"key":"2176_CR249","doi-asserted-by":"publisher","first-page":"31108","DOI":"10.1074\/jbc.274.43.31108","volume":"274","author":"MP Scheid","year":"1999","unstructured":"Scheid, M. P., Schubert, K. M. & Duronio, V. Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK\/Erk kinase. J. Biol. Chem. 274, 31108\u201331113 (1999).","journal-title":"J. Biol. Chem."},{"key":"2176_CR250","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1126\/science.286.5443.1358","volume":"286","author":"A Bonni","year":"1999","unstructured":"Bonni, A. et al. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286, 1358\u20131362 (1999).","journal-title":"Science"},{"key":"2176_CR251","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1042\/bj3490547","volume":"349","author":"JM Lizcano","year":"2000","unstructured":"Lizcano, J. M., Morrice, N. & Cohen, P. Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochem J. 349, 547\u2013557 (2000).","journal-title":"Biochem J."},{"key":"2176_CR252","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.360","volume":"4","author":"JM Eichhorn","year":"2013","unstructured":"Eichhorn, J. M. et al. Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death. Cell Death Dis. 4, e834 (2013).","journal-title":"Cell Death Dis."},{"key":"2176_CR253","doi-asserted-by":"publisher","first-page":"26865","DOI":"10.1016\/S0021-9258(18)47099-8","volume":"269","author":"WS May","year":"1994","unstructured":"May, W. S. et al. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J. Biol. Chem. 269, 26865\u201326870 (1994).","journal-title":"J. Biol. Chem."},{"key":"2176_CR254","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/sj.leu.2402090","volume":"15","author":"PP Ruvolo","year":"2001","unstructured":"Ruvolo, P. P., Deng, X. & May, W. S. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 15, 515\u2013522 (2001).","journal-title":"Leukemia"},{"key":"2176_CR255","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.febslet.2004.06.003","volume":"569","author":"Y Tamura","year":"2004","unstructured":"Tamura, Y., Simizu, S. & Osada, H. The phosphorylation status and anti-apoptotic activity of Bcl-2 are regulated by ERK and protein phosphatase 2A on the mitochondria. FEBS Lett. 569, 249\u2013255 (2004).","journal-title":"FEBS Lett."},{"key":"2176_CR256","doi-asserted-by":"publisher","first-page":"23003","DOI":"10.1074\/jbc.M602648200","volume":"281","author":"SS Lin","year":"2006","unstructured":"Lin, S. S. et al. PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J. Biol. Chem. 281, 23003\u201323012 (2006).","journal-title":"J. Biol. Chem."},{"key":"2176_CR257","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/sj.emboj.7600104","volume":"23","author":"MC Bassik","year":"2004","unstructured":"Bassik, M. C. et al. Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis. EMBO J. 23, 1207\u20131216 (2004).","journal-title":"EMBO J."},{"key":"2176_CR258","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1128\/MCB.20.5.1886-1896.2000","volume":"20","author":"K Breitschopf","year":"2000","unstructured":"Breitschopf, K. et al. Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol. Cell Biol. 20, 1886\u20131896 (2000).","journal-title":"Mol. Cell Biol."},{"key":"2176_CR259","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.1158\/0008-5472.CAN-05-0686","volume":"65","author":"Y Fernandez","year":"2005","unstructured":"Fernandez, Y. et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res. 65, 6294\u20136304 (2005).","journal-title":"Cancer Res."},{"key":"2176_CR260","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","volume":"107","author":"P Perez-Galan","year":"2006","unstructured":"Perez-Galan, P. et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107, 257\u2013264 (2006).","journal-title":"Blood"},{"key":"2176_CR261","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-05-0676","volume":"65","author":"JZ Qin","year":"2005","unstructured":"Qin, J. Z. et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 65, 6282\u20136293 (2005).","journal-title":"Cancer Res."},{"key":"2176_CR262","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1158\/1535-7163.MCT-04-0260","volume":"4","author":"M Nikrad","year":"2005","unstructured":"Nikrad, M. et al. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol. Cancer Ther. 4, 443\u2013449 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"2176_CR263","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1038\/sj.onc.1208683","volume":"24","author":"H Zhu","year":"2005","unstructured":"Zhu, H. et al. Bik\/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 24, 4993\u20134999 (2005).","journal-title":"Oncogene"},{"key":"2176_CR264","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1073\/pnas.070047997","volume":"97","author":"B Li","year":"2000","unstructured":"Li, B. & Dou, Q. P. Bax degradation by the ubiquitin\/proteasome-dependent pathway: involvement in tumor survival and progression. Proc. Natl Acad. Sci. USA 97, 3850\u20133855 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR265","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02923-x","volume":"11","author":"MC Albert","year":"2020","unstructured":"Albert, M. C. et al. CHIP ubiquitylates NOXA and induces its lysosomal degradation in response to DNA damage. Cell Death Dis. 11, 740 (2020).","journal-title":"Cell Death Dis."},{"key":"2176_CR266","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/cdd.2017.30","volume":"24","author":"EM Carrington","year":"2017","unstructured":"Carrington, E. M. et al. Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo. Cell Death Differ. 24, 878\u2013888 (2017).","journal-title":"Cell Death Differ."},{"key":"2176_CR267","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3390\/biomedicines11061666","volume":"11","author":"M Michalski","year":"2023","unstructured":"Michalski, M. et al. Simultaneous inhibition of Mcl-1 and Bcl-2 induces synergistic cell death in hepatocellular carcinoma. Biomedicines 11, 1666 (2023).","journal-title":"Biomedicines"},{"key":"2176_CR268","doi-asserted-by":"publisher","first-page":"36353","DOI":"10.18632\/oncotarget.9217","volume":"7","author":"W Nakajima","year":"2016","unstructured":"Nakajima, W. et al. DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa\/MCL-1\/CDK2 complex. Oncotarget 7, 36353\u201336365 (2016).","journal-title":"Oncotarget"},{"key":"2176_CR269","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/cells3020418","volume":"3","author":"B Mojsa","year":"2014","unstructured":"Mojsa, B., Lassot, I. & Desagher, S. Mcl-1 ubiquitination: unique regulation of an essential survival protein. Cells 3, 418\u2013437 (2014).","journal-title":"Cells"},{"key":"2176_CR270","first-page":"33","volume":"109","author":"GLQ Tang","year":"2024","unstructured":"Tang, G. L. Q., Lai, J. X. H. & Pervaiz, S. Ubiquitin-proteasome pathway-mediated regulation of the Bcl-2 family: effects and therapeutic approaches. Haematologica 109, 33\u201343 (2024).","journal-title":"Haematologica"},{"key":"2176_CR271","first-page":"5628","volume":"55","author":"H Turley","year":"1995","unstructured":"Turley, H. et al. The distribution of the deleted in colon cancer (DCC) protein in human tissues. Cancer Res. 55, 5628\u20135631 (1995).","journal-title":"Cancer Res."},{"key":"2176_CR272","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1349-7006.1994.tb02400.x","volume":"85","author":"A Ayhan","year":"1994","unstructured":"Ayhan, A. et al. Loss of heterozygosity at the bcl-2 gene locus and expression of bcl-2 in human gastric and colorectal carcinomas. Jpn J. Cancer Res. 85, 584\u2013591 (1994).","journal-title":"Jpn J. Cancer Res."},{"key":"2176_CR273","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905 (2010).","journal-title":"Nature"},{"key":"2176_CR274","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576.e516 (2017).","journal-title":"Cell"},{"key":"2176_CR275","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nrd2658","volume":"7","author":"G Lessene","year":"2008","unstructured":"Lessene, G., Czabotar, P. E. & Colman, P. M. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 7, 989\u20131000 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2176_CR276","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","volume":"113","author":"M Vogler","year":"2009","unstructured":"Vogler, M. et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113, 4403\u20134413 (2009).","journal-title":"Blood"},{"key":"2176_CR277","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason, K. D. et al. Programmed anuclear cell death delimits platelet life span. Cell 128, 1173\u20131186 (2007).","journal-title":"Cell"},{"key":"2176_CR278","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","volume":"118","author":"SM Schoenwaelder","year":"2011","unstructured":"Schoenwaelder, S. M. et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 118, 1663\u20131674 (2011).","journal-title":"Blood"},{"key":"2176_CR279","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson, W. H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11, 1149\u20131159 (2010).","journal-title":"Lancet Oncol."},{"key":"2176_CR280","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts, A. W. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30, 488\u2013496 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2176_CR281","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","volume":"56","author":"TJ Kipps","year":"2015","unstructured":"Kipps, T. J. et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk. Lymphoma 56, 2826\u20132833 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"2176_CR282","doi-asserted-by":"publisher","first-page":"7145","DOI":"10.1182\/blood-2011-03-344812","volume":"117","author":"M Vogler","year":"2011","unstructured":"Vogler, M. et al. BCL2\/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 117, 7145\u20137154 (2011).","journal-title":"Blood"},{"key":"2176_CR283","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","volume":"123","author":"R Rampal","year":"2014","unstructured":"Rampal, R. et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 123, e123\u2013133 (2014).","journal-title":"Blood"},{"key":"2176_CR284","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1200\/JCO.21.02188","volume":"40","author":"CN Harrison","year":"2022","unstructured":"Harrison, C. N. et al. Addition of Navitoclax to ongoing Ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: Phase II Safety and Efficacy. J. Clin. Oncol. 40, 1671\u20131680 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2176_CR285","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S2352-3026(22)00116-8","volume":"9","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju, N. et al. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematol. 9, e434\u2013e444 (2022).","journal-title":"Lancet Haematol."},{"key":"2176_CR286","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1182\/blood-2023-173509","volume":"142","author":"N Pemmaraju","year":"2023","unstructured":"Pemmaraju, N. et al. Transform-1: A randomized, double-blind, placebo-controlled, multicenter, International Phase 3 study of Navitoclax in combination with Ruxolitinib Versus Ruxolitinib plus placebo in patients with untreated myelofibrosis. Blood 142, 620\u2013620 (2023).","journal-title":"Blood"},{"key":"2176_CR287","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/bjh.12457","volume":"163","author":"M Vogler","year":"2013","unstructured":"Vogler, M., Dinsdale, D., Dyer, M. J. & Cohen, G. M. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br. J. Haematol. 163, 139\u2013142 (2013).","journal-title":"Br. J. Haematol."},{"key":"2176_CR288","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","volume":"18","author":"JF Seymour","year":"2017","unstructured":"Seymour, J. F. et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 18, 230\u2013240 (2017).","journal-title":"Lancet Oncol."},{"key":"2176_CR289","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","volume":"19","author":"JA Jones","year":"2018","unstructured":"Jones, J. A. et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 19, 65\u201375 (2018).","journal-title":"Lancet Oncol."},{"key":"2176_CR290","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer, K. et al. Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions. N. Engl. J. Med. 380, 2225\u20132236 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2176_CR291","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37648-w","volume":"14","author":"O Al-Sawaf","year":"2023","unstructured":"Al-Sawaf, O. et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat. Commun. 14, 2147 (2023).","journal-title":"Nat. Commun."},{"key":"2176_CR292","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2176_CR293","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz, K. W. et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am. J. Hematol. 99, 615\u2013624 (2024).","journal-title":"Am. J. Hematol."},{"key":"2176_CR294","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","volume":"26","author":"S Jin","year":"2020","unstructured":"Jin, S. et al. 5-Azacitidine induces NOXA to Prime AML cells for Venetoclax-mediated apoptosis. Clin. Cancer Res. 26, 3371\u20133383 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2176_CR295","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3324\/haematol.2020.272609","volume":"107","author":"D Cojocari","year":"2022","unstructured":"Cojocari, D. et al. Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia. Haematologica 107, 825\u2013835 (2022).","journal-title":"Haematologica"},{"key":"2176_CR296","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/ijms25010484","volume":"25","author":"R Mishra","year":"2023","unstructured":"Mishra, R., Zokaei Nikoo, M., Veeraballi, S. & Singh, A. Venetoclax and hypomethylating agent combination in myeloid malignancies: mechanisms of synergy and challenges of resistance. Int. J. Mol. Sci. 25, 484 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2176_CR297","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2020009081","volume":"138","author":"JB Lee","year":"2021","unstructured":"Lee, J. B. et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood 138, 234\u2013245 (2021).","journal-title":"Blood"},{"key":"2176_CR298","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids, M. S. et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J. Clin. Oncol. 35, 826\u2013833 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2176_CR299","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00002","volume":"3","author":"HS Walter","year":"2019","unstructured":"Walter, H. S. et al. Successful treatment of primary cutaneous diffuse large B-cell lymphoma leg type with single-agent Venetoclax. JCO Precis Oncol. 3, 1\u20135 (2019).","journal-title":"JCO Precis Oncol."},{"key":"2176_CR300","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-15-1191","volume":"22","author":"M Klanova","year":"2016","unstructured":"Klanova, M. et al. Targeting of BCL2 family proteins with ABT-199 and Homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-cell lymphoma. Clin. Cancer Res. 22, 1138\u20131149 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2176_CR301","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3324\/haematol.2019.220525","volume":"105","author":"VM Smith","year":"2020","unstructured":"Smith, V. M. et al. Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. Haematologica 105, 2150\u20132163 (2020).","journal-title":"Haematologica"},{"key":"2176_CR302","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05815-z","volume":"9","author":"RS Soderquist","year":"2018","unstructured":"Soderquist, R. S. et al. Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity. Nat. Commun. 9, 3513 (2018).","journal-title":"Nat. Commun."},{"key":"2176_CR303","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","volume":"133","author":"K Bojarczuk","year":"2019","unstructured":"Bojarczuk, K. et al. Targeted inhibition of PI3Kalpha\/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood 133, 70\u201380 (2019).","journal-title":"Blood"},{"key":"2176_CR304","first-page":"1815","volume":"5","author":"HP Kiem","year":"1990","unstructured":"Kiem, H. P. et al. Concurrent activation of c-myc and inactivation of bcl-2 by chromosomal translocation in a lymphoblastic lymphoma cell line. Oncogene 5, 1815\u20131819 (1990).","journal-title":"Oncogene"},{"key":"2176_CR305","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41375-023-02120-7","volume":"38","author":"W Ren","year":"2024","unstructured":"Ren, W. et al. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis. Leukemia 38, 610\u2013620 (2024).","journal-title":"Leukemia"},{"key":"2176_CR306","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41379-021-00962-z","volume":"35","author":"J Roh","year":"2022","unstructured":"Roh, J. et al. BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis. Mod. Pathol. 35, 480\u2013488 (2022).","journal-title":"Mod. Pathol."},{"key":"2176_CR307","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood.2020006578","volume":"137","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser, F. et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood 137, 600\u2013609 (2021).","journal-title":"Blood"},{"key":"2176_CR308","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ajh.26809","volume":"98","author":"EA Lasater","year":"2023","unstructured":"Lasater, E. A. et al. Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R\/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study. Am. J. Hematol. 98, 449\u2013463 (2023).","journal-title":"Am. J. Hematol."},{"key":"2176_CR309","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar, S. et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood 130, 2401\u20132409 (2017).","journal-title":"Blood"},{"key":"2176_CR310","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/blood.2020007899","volume":"137","author":"VA Gupta","year":"2021","unstructured":"Gupta, V. A. et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood 137, 3604\u20133615 (2021).","journal-title":"Blood"},{"key":"2176_CR311","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar, S. K. et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 21, 1630\u20131642 (2020).","journal-title":"Lancet Oncol."},{"key":"2176_CR312","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","volume":"21","author":"SE Karol","year":"2020","unstructured":"Karol, S. E. et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 21, 551\u2013560 (2020).","journal-title":"Lancet Oncol."},{"key":"2176_CR313","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1182\/bloodadvances.2023010113","volume":"7","author":"R Masetti","year":"2023","unstructured":"Masetti, R. et al. Venetoclax-based therapies in pediatric advanced MDS and relapsed\/refractory AML: a multicenter retrospective analysis. Blood Adv. 7, 4366\u20134370 (2023).","journal-title":"Blood Adv."},{"key":"2176_CR314","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat, V. A. et al. Venetoclax and Navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 11, 1440\u20131453 (2021).","journal-title":"Cancer Discov."},{"key":"2176_CR315","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ccell.2016.11.011","volume":"31","author":"KA Sarosiek","year":"2017","unstructured":"Sarosiek, K. A. et al. Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissue-specific sensitivity to cancer therapeutics. Cancer Cell. 31, 142\u2013156 (2017).","journal-title":"Cancer Cell."},{"key":"2176_CR316","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135, 791\u2013803 (2020).","journal-title":"Blood"},{"key":"2176_CR317","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei, S. et al. Monocytic subclones confer resistance to Venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 10, 536\u2013551 (2020).","journal-title":"Cancer Discov."},{"key":"2176_CR318","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","volume":"9","author":"P Blombery","year":"2019","unstructured":"Blombery, P. et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 9, 342\u2013353 (2019).","journal-title":"Cancer Discov."},{"key":"2176_CR319","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.3390\/ijms24065802","volume":"24","author":"L Kotmayer","year":"2023","unstructured":"Kotmayer, L. et al. Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax. Int. J. Mol. Sci. 24, 5802 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2176_CR320","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10363-1","volume":"10","author":"RW Birkinshaw","year":"2019","unstructured":"Birkinshaw, R. W. et al. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nat. Commun. 10, 2385 (2019).","journal-title":"Nat. Commun."},{"key":"2176_CR321","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2022016040","volume":"140","author":"R Thijssen","year":"2022","unstructured":"Thijssen, R. et al. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. Blood 140, 2127\u20132141 (2022).","journal-title":"Blood"},{"key":"2176_CR322","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Guieze","year":"2019","unstructured":"Guieze, R. et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 36, 369\u2013384.e313 (2019).","journal-title":"Cancer Cell."},{"key":"2176_CR323","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1182\/blood.2021012775","volume":"139","author":"P Blombery","year":"2022","unstructured":"Blombery, P. et al. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood 139, 1198\u20131207 (2022).","journal-title":"Blood"},{"key":"2176_CR324","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood.2022016090","volume":"141","author":"DM Moujalled","year":"2023","unstructured":"Moujalled, D. M. et al. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia. Blood 141, 634\u2013644 (2023).","journal-title":"Blood"},{"key":"2176_CR325","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02867-2","volume":"11","author":"A Roca-Portoles","year":"2020","unstructured":"Roca-Portoles, A. et al. Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. Cell Death Dis. 11, 616 (2020).","journal-title":"Cell Death Dis."},{"key":"2176_CR326","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101580","volume":"5","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. Cell Rep. Med. 5, 101580 (2024).","journal-title":"Cell Rep. Med."},{"key":"2176_CR327","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1080\/15548627.2015.1017191","volume":"11","author":"JM Pedro","year":"2015","unstructured":"Pedro, J. M. et al. BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy. Autophagy 11, 452\u2013459 (2015).","journal-title":"Autophagy"},{"key":"2176_CR328","doi-asserted-by":"publisher","first-page":"37204","DOI":"10.1074\/jbc.M113.528067","volume":"288","author":"P Ma","year":"2013","unstructured":"Ma, P. et al. Interaction of Bcl-2 with the autophagy-related GABAA receptor-associated protein (GABARAP): biophysical characterization and functional implications. J. Biol. Chem. 288, 37204\u201337215 (2013).","journal-title":"J. Biol. Chem."},{"key":"2176_CR329","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1593\/neo.121392","volume":"15","author":"D Trisciuoglio","year":"2013","unstructured":"Trisciuoglio, D. et al. Removal of the BH4 domain from Bcl-2 protein triggers an autophagic process that impairs tumor growth. Neoplasia 15, 315\u2013327 (2013).","journal-title":"Neoplasia"},{"key":"2176_CR330","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/carcin\/bgx016","volume":"38","author":"C Gabellini","year":"2017","unstructured":"Gabellini, C., Trisciuoglio, D. & Del Bufalo, D. Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain. Carcinogenesis 38, 579\u2013587 (2017).","journal-title":"Carcinogenesis"},{"key":"2176_CR331","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/cdd.2017.22","volume":"24","author":"A Gross","year":"2017","unstructured":"Gross, A. & Katz, S. G. Non-apoptotic functions of BCL-2 family proteins. Cell Death Differ. 24, 1348\u20131358 (2017).","journal-title":"Cell Death Differ."},{"key":"2176_CR332","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.tcb.2020.03.004","volume":"30","author":"SJF Chong","year":"2020","unstructured":"Chong, S. J. F. et al. Noncanonical cell fate regulation by Bcl-2 proteins. Trends Cell Biol. 30, 537\u2013555 (2020).","journal-title":"Trends Cell Biol."},{"key":"2176_CR333","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3389\/fonc.2018.00645","volume":"8","author":"B Tessoulin","year":"2018","unstructured":"Tessoulin, B. et al. BCL2-family dysregulation in B-cell malignancies: from gene expression regulation to a targeted therapy biomarker. Front Oncol. 8, 645 (2018).","journal-title":"Front Oncol."},{"key":"2176_CR334","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/pros.23843","volume":"79","author":"AB Pilling","year":"2019","unstructured":"Pilling, A. B. & Hwang, C. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide. Prostate 79, 1347\u20131359 (2019).","journal-title":"Prostate"},{"key":"2176_CR335","doi-asserted-by":"publisher","first-page":"107375","DOI":"10.1016\/j.jbc.2024.107375","volume":"300","author":"L Duan","year":"2024","unstructured":"Duan, L., Tadi, M. J., O\u2019Hara, K. M. & Maki, C. G. Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells. J. Biol. Chem. 300, 107375 (2024).","journal-title":"J. Biol. Chem."},{"key":"2176_CR336","doi-asserted-by":"publisher","first-page":"20075","DOI":"10.18632\/oncotarget.24744","volume":"9","author":"P Casara","year":"2018","unstructured":"Casara, P. et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget 9, 20075\u201320088 (2018).","journal-title":"Oncotarget"},{"key":"2176_CR337","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1158\/1538-7445.AM2021-1276","volume":"81","author":"AL Tiran","year":"2021","unstructured":"Tiran, A. L. et al. Abstract 1276: Identification of S65487\/VOB560 as a potent and selective intravenous 2nd-generation BCL-2 inhibitor active in wild-type and clinical mutants resistant to Venetoclax. Cancer Res. 81, 1276 (2021).","journal-title":"Cancer Res."},{"key":"2176_CR338","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1182\/blood.2023019706","volume":"143","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood 143, 1825\u20131836 (2024).","journal-title":"Blood"},{"key":"2176_CR339","doi-asserted-by":"publisher","first-page":"7836","DOI":"10.1021\/acs.jmedchem.4c00027","volume":"67","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. Discovery of the clinical candidate Sonrotoclax (BGB-11417), a highly potent and selective inhibitor for both WT and G101V mutant Bcl-2. J. Med. Chem. 67, 7836\u20137858 (2024).","journal-title":"J. Med. Chem."},{"key":"2176_CR340","doi-asserted-by":"publisher","first-page":"TPS7090","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7090","volume":"42","author":"H-P Lee","year":"2024","unstructured":"Lee, H.-P. et al. BGB-11417-203: An ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenstr\u00f6m macroglobulinemia. J. Clin. Oncol. 42, TPS7090 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2176_CR341","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/blood-2023-179541","volume":"142","author":"CS Tam","year":"2023","unstructured":"Tam, C. S. et al. Combination treatment with Sonrotoclax (BGB-11417), a second-generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma (TN-CLL\/SLL): Data from an ongoing Phase 1\/2 Study. Blood 142, 327\u2013327 (2023).","journal-title":"Blood"},{"key":"2176_CR342","doi-asserted-by":"publisher","first-page":"TPS7087","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7087","volume":"42","author":"M Shadman","year":"2024","unstructured":"Shadman, M. et al. CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-na\u00efve (TN) CLL. J. Clin. Oncol. 42, TPS7087 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2176_CR343","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1158\/1078-0432.CCR-21-4037","volume":"28","author":"J Deng","year":"2022","unstructured":"Deng, J. et al. Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy. Clin. Cancer Res. 28, 5455\u20135468 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2176_CR344","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-22-3321","volume":"29","author":"S Ailawadhi","year":"2023","unstructured":"Ailawadhi, S. et al. Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or refractory chronic lymphocytic leukemia and other hematologic malignancies: first-in-human open-label trial. Clin. Cancer Res. 29, 2385\u20132393 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2176_CR345","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1078-0432.CCR-22-0978","volume":"29","author":"Y Zhai","year":"2023","unstructured":"Zhai, Y. et al. Lisaftoclax in combination with Alrizomadlin overcomes Venetoclax resistance in acute myeloid leukemia and acute lymphoblastic leukemia: preclinical studies. Clin. Cancer Res. 29, 183\u2013196 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2176_CR346","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1158\/1538-7445.AM2019-2497","volume":"79","author":"S Lin","year":"2019","unstructured":"Lin, S. et al. Abstract 2497: FCN-338, a novel and selective Bcl-2 inhibitor, exhibits potent anti-tumor activity in B-cell lymphoma. Cancer Res. 79, 2497 (2019).","journal-title":"Cancer Res."},{"key":"2176_CR347","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/1538-7445.AM2021-1258","volume":"81","author":"B Brandhuber","year":"2021","unstructured":"Brandhuber, B. et al. Abstract 1258: Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor. Cancer Res. 81, 1258 (2021).","journal-title":"Cancer Res."},{"key":"2176_CR348","doi-asserted-by":"publisher","first-page":"e216785f","DOI":"10.1097\/01.HS9.0000969448.21678.5f","volume":"7","author":"M Kwiatek","year":"2023","unstructured":"Kwiatek, M. et al. P636: A First-In-Human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies. Hemasphere 7, e216785f (2023).","journal-title":"Hemasphere"},{"key":"2176_CR349","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/01.HS9.0000845616.77820.49","volume":"6","author":"W Jurczak","year":"2022","unstructured":"Jurczak, W. et al. P683: A First-In-Human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (Trial in progress). HemaSphere 6, 579\u2013580 (2022).","journal-title":"HemaSphere"},{"key":"2176_CR350","doi-asserted-by":"publisher","first-page":"TPS7071","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7071","volume":"40","author":"AR Walker","year":"2022","unstructured":"Walker, A. R. et al. Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). J. Clin. Oncol. 40, TPS7071 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2176_CR351","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000968876.25462.61","volume":"7","author":"K Koenig","year":"2023","unstructured":"Koenig, K. et al. P492: safety and efficacy of LP-108 as monotherapy and combined with azacitidine in patients with relapsed\/refractory myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia. HemaSphere 7, e2546261 (2023).","journal-title":"HemaSphere"},{"key":"2176_CR352","doi-asserted-by":"publisher","first-page":"S596","DOI":"10.1016\/j.annonc.2024.08.851","volume":"35","author":"J Qi","year":"2024","unstructured":"Qi, J. et al. 800MO First report of BCL-2 inhibitor TQB3909 in pts with relapsed or refractory non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML): Data from a phase I study. Ann. Oncol. 35, S596 (2024).","journal-title":"Ann. Oncol."},{"key":"2176_CR353","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nchembio.1246","volume":"9","author":"G Lessene","year":"2013","unstructured":"Lessene, G. et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat. Chem. Biol. 9, 390\u2013397 (2013).","journal-title":"Nat. Chem. Biol."},{"key":"2176_CR354","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1158\/0008-5472.CAN-16-3424","volume":"77","author":"G Karpel-Massler","year":"2017","unstructured":"Karpel-Massler, G. et al. Inhibition of mitochondrial matrix Chaperones and antiapoptotic Bcl-2 family proteins empower antitumor therapeutic responses. Cancer Res. 77, 3513\u20133526 (2017).","journal-title":"Cancer Res."},{"key":"2176_CR355","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1038\/s41388-020-1212-9","volume":"39","author":"M Bessou","year":"2020","unstructured":"Bessou, M. et al. The apoptosis inhibitor Bcl-xL controls breast cancer cell migration through mitochondria-dependent reactive oxygen species production. Oncogene 39, 3056\u20133074 (2020).","journal-title":"Oncogene"},{"key":"2176_CR356","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1158\/2767-9764.CRC-22-0024","volume":"2","author":"AM Pesch","year":"2022","unstructured":"Pesch, A. M. et al. Bcl-xL inhibition radiosensitizes PIK3CA\/PTEN wild-type triple negative breast cancers with low Mcl-1 expression. Cancer Res. Commun. 2, 679\u2013693 (2022).","journal-title":"Cancer Res. Commun."},{"key":"2176_CR357","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1021\/ml5001867","volume":"5","author":"ZF Tao","year":"2014","unstructured":"Tao, Z. F. et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med. Chem. Lett. 5, 1088\u20131093 (2014).","journal-title":"ACS Med. Chem. Lett."},{"key":"2176_CR358","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1021\/acsmedchemlett.9b00568","volume":"11","author":"L Wang","year":"2020","unstructured":"Wang, L. et al. Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-X(L) inhibitor. ACS Med. Chem. Lett. 11, 1829\u20131836 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"2176_CR359","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0397-y","volume":"14","author":"H Zhang","year":"2015","unstructured":"Zhang, H. et al. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer. Mol. Cancer 14, 126 (2015).","journal-title":"Mol. Cancer"},{"key":"2176_CR360","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110374","volume":"38","author":"P Ramesh","year":"2022","unstructured":"Ramesh, P. et al. BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer. Cell Rep. 38, 110374 (2022).","journal-title":"Cell Rep."},{"key":"2176_CR361","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1021\/acsmedchemlett.1c00162","volume":"12","author":"ZF Tao","year":"2021","unstructured":"Tao, Z. F. et al. Structure-based design of A-1293102, a potent and selective BCL-X(L) inhibitor. ACS Med. Chem. Lett. 12, 1011\u20131016 (2021).","journal-title":"ACS Med. Chem. Lett."},{"key":"2176_CR362","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1002\/cam4.3090","volume":"9","author":"H Yi","year":"2020","unstructured":"Yi, H. et al. Bcl-2\/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 9, 4197\u20134206 (2020).","journal-title":"Cancer Med."},{"key":"2176_CR363","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100798","volume":"29","author":"W Yao","year":"2022","unstructured":"Yao, W. et al. Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2\/Bcl-X(L) dual inhibitor that induces Bax-dependent apoptosis. Neoplasia 29, 100798 (2022).","journal-title":"Neoplasia"},{"key":"2176_CR364","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/mc.23458","volume":"61","author":"L Qian","year":"2022","unstructured":"Qian, L. et al. Therapeutic potential of the novel Bcl-2\/Bcl-X(L) dual inhibitor, APG1252, alone or in combination against non-small cell lung cancer. Mol. Carcinog. 61, 1031\u20131042 (2022).","journal-title":"Mol. Carcinog."},{"key":"2176_CR365","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/1078-0432.CCR-23-1525","volume":"30","author":"NJ Lakhani","year":"2024","unstructured":"Lakhani, N. J. et al. First-in-human study with preclinical data of BCL-2\/BCL-xL inhibitor pelcitoclax in locally advanced or metastatic solid tumors. Clin. Cancer Res. 30, 506\u2013521 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2176_CR366","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","volume":"19","author":"S Wuilleme-Toumi","year":"2005","unstructured":"Wuilleme-Toumi, S. et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19, 1248\u20131252 (2005).","journal-title":"Leukemia"},{"key":"2176_CR367","doi-asserted-by":"publisher","first-page":"7301","DOI":"10.2147\/OTT.S146228","volume":"11","author":"W Xiang","year":"2018","unstructured":"Xiang, W., Yang, C. Y. & Bai, L. MCL-1 inhibition in cancer treatment. Onco Targets Ther. 11, 7301\u20137314 (2018).","journal-title":"Onco Targets Ther."},{"key":"2176_CR368","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.2147\/OTT.S194549","volume":"12","author":"XX Li","year":"2019","unstructured":"Li, X. X. et al. Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia. Onco Targets Ther. 12, 3295\u20133304 (2019).","journal-title":"Onco Targets Ther."},{"key":"2176_CR369","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477\u2013482 (2016).","journal-title":"Nature"},{"key":"2176_CR370","doi-asserted-by":"publisher","first-page":"13762","DOI":"10.1021\/acs.jmedchem.0c01234","volume":"63","author":"Z Szlavik","year":"2020","unstructured":"Szlavik, Z. et al. Discovery of S64315, a potent and selective Mcl-1 inhibitor. J. Med Chem. 63, 13762\u201313795 (2020).","journal-title":"J. Med Chem."},{"key":"2176_CR371","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s43856-023-00380-z","volume":"3","author":"J Yuda","year":"2023","unstructured":"Yuda, J. et al. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun. Med. 3, 154 (2023).","journal-title":"Commun. Med."},{"key":"2176_CR372","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1101\/gad.215871.113","volume":"27","author":"RL Thomas","year":"2013","unstructured":"Thomas, R. L. et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 27, 1365\u20131377 (2013).","journal-title":"Genes Dev."},{"key":"2176_CR373","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","volume":"8","author":"S Caenepeel","year":"2018","unstructured":"Caenepeel, S. et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 8, 1582\u20131597 (2018).","journal-title":"Cancer Discov."},{"key":"2176_CR374","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2221967120","volume":"120","author":"D Hargreaves","year":"2023","unstructured":"Hargreaves, D. et al. Design of rigid protein-protein interaction inhibitors enables targeting of undruggable Mcl-1. Proc. Natl Acad. Sci. USA 120, e2221967120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR375","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1158\/1538-7445.AM2020-6218","volume":"80","author":"S Caenepeel","year":"2020","unstructured":"Caenepeel, S. et al. Abstract 6218: Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor. Cancer Res. 80, 6218\u20136218 (2020).","journal-title":"Cancer Res."},{"key":"2176_CR376","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","volume":"91","author":"T Tsao","year":"2012","unstructured":"Tsao, T. et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann. Hematol. 91, 1861\u20131870 (2012).","journal-title":"Ann. Hematol."},{"key":"2176_CR377","doi-asserted-by":"publisher","first-page":"CT172","DOI":"10.1158\/1538-7445.AM2023-CT172","volume":"83","author":"G Falchook","year":"2023","unstructured":"Falchook, G. et al. Abstract CT172: A phase 1, open-label, dose-escalation study of PRT1419, a selective induced myeloid leukemia cell differentiation protein (MCL-1) inhibitor, in patients (pts) with advanced\/metastatic solid tumors. Cancer Res. 83, CT172\u2013CT172 (2023).","journal-title":"Cancer Res."},{"key":"2176_CR378","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1158\/1538-7445.AM2022-3696","volume":"82","author":"CK Matson","year":"2022","unstructured":"Matson, C. K. et al. Abstract 3696: GS-9716: A potent, selective and orally bioavailable small molecule inhibitor of MCL1 for the treatment of cancer. Cancer Res. 82, 3696 (2022).","journal-title":"Cancer Res."},{"key":"2176_CR379","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/cmdc.202100011","volume":"16","author":"F Daressy","year":"2021","unstructured":"Daressy, F. et al. Drimane derivatives as the first examples of covalent BH3 mimetics that target MCL-1. ChemMedChem 16, 1788\u20131797 (2021).","journal-title":"ChemMedChem"},{"key":"2176_CR380","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113546","volume":"154","author":"F Daressy","year":"2022","unstructured":"Daressy, F. et al. NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes. Biomed. Pharmacother. 154, 113546 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"2176_CR381","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122433","volume":"630","author":"L Seguy","year":"2023","unstructured":"Seguy, L. et al. In vitro evaluation of NA1-115-7-loaded nanoemulsions, an MCL-1-specific inhibitor of natural origin, intended to treat B-cell lymphoproliferative disorders after oral administration. Int J. Pharm. 630, 122433 (2023).","journal-title":"Int J. Pharm."},{"key":"2176_CR382","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1126\/science.1099191","volume":"305","author":"LD Walensky","year":"2004","unstructured":"Walensky, L. D. et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466\u20131470 (2004).","journal-title":"Science"},{"key":"2176_CR383","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.molcel.2006.08.020","volume":"24","author":"LD Walensky","year":"2006","unstructured":"Walensky, L. D. et al. A stapled BID BH3 helix directly binds and activates BAX. Mol. Cell. 24, 199\u2013210 (2006).","journal-title":"Mol. Cell."},{"key":"2176_CR384","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.18632\/oncotarget.27262","volume":"10","author":"A Hadji","year":"2019","unstructured":"Hadji, A. et al. Preferential targeting of MCL-1 by a hydrocarbon-stapled BIM BH3 peptide. Oncotarget 10, 6219\u20136233 (2019).","journal-title":"Oncotarget"},{"key":"2176_CR385","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1172\/JCI46231","volume":"122","author":"JL LaBelle","year":"2012","unstructured":"LaBelle, J. L. et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J. Clin. Invest. 122, 2018\u20132031 (2012).","journal-title":"J. Clin. Invest."},{"key":"2176_CR386","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1016\/j.celrep.2018.08.089","volume":"24","author":"RM Guerra","year":"2018","unstructured":"Guerra, R. M. et al. Precision targeting of BFL-1\/A1 and an ATM co-dependency in human cancer. Cell Rep. 24, 3393\u20133403 e3395 (2018).","journal-title":"Cell Rep."},{"key":"2176_CR387","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.chembiol.2016.07.022","volume":"23","author":"AJ Huhn","year":"2016","unstructured":"Huhn, A. J. et al. Selective covalent targeting of anti-apoptotic BFL-1 by Cysteine-reactive stapled peptide inhibitors. Cell Chem. Biol. 23, 1123\u20131134 (2016).","journal-title":"Cell Chem. Biol."},{"key":"2176_CR388","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41594-020-0458-9","volume":"27","author":"KJ Korshavn","year":"2020","unstructured":"Korshavn, K. J. et al. A redox switch regulates the structure and function of anti-apoptotic BFL-1. Nat. Struct. Mol. Biol. 27, 781\u2013789 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2176_CR389","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.chembiol.2024.06.016","volume":"31","author":"SX Tang","year":"2024","unstructured":"Tang, S. X. et al. Dissecting the neuroprotective interaction between the BH4 domain of BCL-w and the IP3 receptor. Cell Chem. Biol. 31, 1815\u20131826 (2024).","journal-title":"Cell Chem. Biol."},{"key":"2176_CR390","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1158\/1078-0432.CCR-21-0715","volume":"27","author":"MN Saleh","year":"2021","unstructured":"Saleh, M. N. et al. Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53. Clin. Cancer Res. 27, 5236\u20135247 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2176_CR391","doi-asserted-by":"publisher","first-page":"9401","DOI":"10.1021\/acs.jmedchem.3c00623","volume":"66","author":"V Guerlavais","year":"2023","unstructured":"Guerlavais, V. et al. Discovery of Sulanemadlin (ALRN-6924), the first cell-permeating, stabilized alpha-helical peptide in clinical development. J. Med Chem. 66, 9401\u20139417 (2023).","journal-title":"J. Med Chem."},{"key":"2176_CR392","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1182\/blood-2010-09-307405","volume":"117","author":"F Zhong","year":"2011","unstructured":"Zhong, F. et al. Induction of Ca(2)+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction. Blood 117, 2924\u20132934 (2011).","journal-title":"Blood"},{"key":"2176_CR393","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.140","volume":"4","author":"H Akl","year":"2013","unstructured":"Akl, H. et al. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2. Cell Death Dis. 4, e632 (2013).","journal-title":"Cell Death Dis."},{"key":"2176_CR394","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41418-018-0142-3","volume":"26","author":"M Bittremieux","year":"2019","unstructured":"Bittremieux, M. et al. Constitutive IP(3) signaling underlies the sensitivity of B-cell cancers to the Bcl-2\/IP(3) receptor disruptor BIRD-2. Cell Death Differ. 26, 531\u2013547 (2019).","journal-title":"Cell Death Differ."},{"key":"2176_CR395","doi-asserted-by":"publisher","first-page":"111656","DOI":"10.18632\/oncotarget.22898","volume":"8","author":"T Vervloessem","year":"2017","unstructured":"Vervloessem, T. et al. Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax. Oncotarget 8, 111656\u2013111671 (2017).","journal-title":"Oncotarget"},{"key":"2176_CR396","doi-asserted-by":"publisher","first-page":"27388","DOI":"10.18632\/oncotarget.4489","volume":"6","author":"AR Lavik","year":"2015","unstructured":"Lavik, A. R. et al. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. Oncotarget 6, 27388\u201327402 (2015).","journal-title":"Oncotarget"},{"key":"2176_CR397","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.355","volume":"6","author":"EF Greenberg","year":"2015","unstructured":"Greenberg, E. F. et al. Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263. Cell Death Dis. 6, e2034 (2015).","journal-title":"Cell Death Dis."},{"key":"2176_CR398","first-page":"809","volume":"41","author":"Q Xie","year":"2018","unstructured":"Xie, Q. et al. TAT\u2011fused IP3R\u2011derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca2+ release. Int J. Mol. Med. 41, 809\u2013817 (2018).","journal-title":"Int J. Mol. Med."},{"key":"2176_CR399","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.ccell.2015.04.010","volume":"27","author":"B Han","year":"2015","unstructured":"Han, B. et al. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell. 27, 852\u2013863 (2015).","journal-title":"Cancer Cell."},{"key":"2176_CR400","doi-asserted-by":"publisher","first-page":"27753","DOI":"10.18632\/oncotarget.8513","volume":"7","author":"J Deng","year":"2016","unstructured":"Deng, J. et al. BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget 7, 27753\u201327763 (2016).","journal-title":"Oncotarget"},{"key":"2176_CR401","doi-asserted-by":"publisher","first-page":"748","DOI":"10.18632\/aging.100828","volume":"7","author":"T Vervloessem","year":"2015","unstructured":"Vervloessem, T., La Rovere, R. & Bultynck, G. Antagonizing Bcl-2\u2019s BH4 domain in cancer. Aging. 7, 748\u2013749 (2015).","journal-title":"Aging."},{"key":"2176_CR402","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02944-6","volume":"11","author":"T Vervloessem","year":"2020","unstructured":"Vervloessem, T. et al. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models. Cell Death Dis. 11, 769 (2020).","journal-title":"Cell Death Dis."},{"key":"2176_CR403","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41418-020-00717-4","volume":"28","author":"RW Birkinshaw","year":"2021","unstructured":"Birkinshaw, R. W. Challenges in small-molecule target identification: a commentary on \u201cBDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models. Cell Death Differ. 28, 1130\u20131132 (2021).","journal-title":"Cell Death Differ."},{"key":"2176_CR404","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10974-4","volume":"23","author":"Y Lin","year":"2023","unstructured":"Lin, Y. et al. CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth. BMC Cancer 23, 479 (2023).","journal-title":"BMC Cancer"},{"key":"2176_CR405","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41401-022-00936-0","volume":"44","author":"JY Zhou","year":"2023","unstructured":"Zhou, J. Y. et al. Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain. Acta Pharm. Sin. 44, 475\u2013485 (2023).","journal-title":"Acta Pharm. Sin."},{"key":"2176_CR406","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1182\/blood.2023022993","volume":"143","author":"JML Casan","year":"2024","unstructured":"Casan, J. M. L. & Seymour, J. F. Degraders upgraded: the rise of PROTACs in hematological malignancies. Blood 143, 1218\u20131230 (2024).","journal-title":"Blood"},{"key":"2176_CR407","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.chembiol.2021.04.002","volume":"28","author":"P Jevtic","year":"2021","unstructured":"Jevtic, P., Haakonsen, D. L. & Rape, M. An E3 ligase guide to the galaxy of small-molecule-induced protein degradation. Cell Chem. Biol. 28, 1000\u20131013 (2021).","journal-title":"Cell Chem. Biol."},{"key":"2176_CR408","doi-asserted-by":"publisher","first-page":"1098331","DOI":"10.3389\/fchem.2023.1098331","volume":"11","author":"H Jiang","year":"2023","unstructured":"Jiang, H., Xiong, H., Gu, S. X. & Wang, M. E3 ligase ligand optimization of Clinical PROTACs. Front Chem. 11, 1098331 (2023).","journal-title":"Front Chem."},{"key":"2176_CR409","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-1","volume":"14","author":"PF Bray","year":"2013","unstructured":"Bray, P. F. et al. The complex transcriptional landscape of the anucleate human platelet. BMC Genomics. 14, 1 (2013).","journal-title":"BMC Genomics."},{"key":"2176_CR410","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao, L. et al. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct. Target Ther. 7, 113 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2176_CR411","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan, S. et al. A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity. Nat. Med. 25, 1938\u20131947 (2019).","journal-title":"Nat. Med."},{"key":"2176_CR412","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-020-00928-9","volume":"13","author":"Y He","year":"2020","unstructured":"He, Y. et al. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J. Hematol. Oncol. 13, 95 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"2176_CR413","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/1535-7163.MCT-21-0474","volume":"21","author":"D Thummuri","year":"2022","unstructured":"Thummuri, D. et al. Overcoming Gemcitabine resistance in pancreatic cancer using the BCL-X(L)-specific degrader DT2216. Mol. Cancer Ther. 21, 184\u2013192 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"2176_CR414","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-022-01296-8","volume":"9","author":"S Khan","year":"2023","unstructured":"Khan, S. et al. Co-targeting BCL-X(L) and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell Death Discov. 9, 1 (2023).","journal-title":"Cell Death Discov."},{"key":"2176_CR415","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112186","volume":"192","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Discovery of PROTAC BCL-X(L) degraders as potent anticancer agents with low on-target platelet toxicity. Eur. J. Med. Chem. 192, 112186 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"2176_CR416","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111826","volume":"41","author":"V Bharti","year":"2022","unstructured":"Bharti, V. et al. BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis. Cell Rep. 41, 111826 (2022).","journal-title":"Cell Rep."},{"key":"2176_CR417","doi-asserted-by":"publisher","first-page":"7476","DOI":"10.7150\/thno.75421","volume":"12","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. The PROTAC selectively degrading Bcl-x(L) represents a novel Hedgehog pathway inhibitor with capacity of combating resistance to Smoothened inhibitors while sparing bone growth. Theranostics 12, 7476\u20137490 (2022).","journal-title":"Theranostics"},{"key":"2176_CR418","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116542","volume":"230","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Sorafenib and SIAIS361034, a novel PROTAC degrader of BCL-x(L), display synergistic antitumor effects on hepatocellular carcinoma with minimal hepatotoxicity. Biochem. Pharmacol. 230, 116542 (2024).","journal-title":"Biochem. Pharmacol."},{"key":"2176_CR419","doi-asserted-by":"publisher","first-page":"14765","DOI":"10.1039\/C9CC07217A","volume":"55","author":"X Zhang","year":"2019","unstructured":"Zhang, X. et al. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X(L). Chem. Commun. 55, 14765\u201314768 (2019).","journal-title":"Chem. Commun."},{"key":"2176_CR420","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112397","volume":"199","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Discovery of IAP-recruiting BCL-X(L) PROTACs as potent degraders across multiple cancer cell lines. Eur. J. Med. Chem. 199, 112397 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"2176_CR421","doi-asserted-by":"publisher","first-page":"14230","DOI":"10.1021\/acs.jmedchem.1c00517","volume":"64","author":"P Pal","year":"2021","unstructured":"Pal, P. et al. Discovery of a novel BCL-X(L) PROTAC degrader with enhanced BCL-2 inhibition. J. Med Chem. 64, 14230\u201314246 (2021).","journal-title":"J. Med Chem."},{"key":"2176_CR422","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.3324\/haematol.2022.281915","volume":"108","author":"Y Jia","year":"2023","unstructured":"Jia, Y. et al. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica 108, 2626\u20132638 (2023).","journal-title":"Haematologica"},{"key":"2176_CR423","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27210-x","volume":"12","author":"D Lv","year":"2021","unstructured":"Lv, D. et al. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat. Commun. 12, 6896 (2021).","journal-title":"Nat. Commun."},{"key":"2176_CR424","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/cells13060528","volume":"13","author":"S Khan","year":"2024","unstructured":"Khan, S. et al. PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer. Cells 13, 258 (2024).","journal-title":"Cells"},{"key":"2176_CR425","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46922-4","volume":"15","author":"D Nayak","year":"2024","unstructured":"Nayak, D. et al. Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nat. Commun. 15, 2743 (2024).","journal-title":"Nat. Commun."},{"key":"2176_CR426","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1182\/blood-2023-184887","volume":"142","author":"Y Xie","year":"2023","unstructured":"Xie, Y. et al. Discovery of BCL-XL heterobifunctional degrader with potentially improved therapeutic window and minimal platelet toxicity for hematological malignancies. Blood 142, 117 (2023).","journal-title":"Blood"},{"key":"2176_CR427","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1021\/acs.jmedchem.9b00919","volume":"62","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1\/Bcl-2 Derived from Nonselective Target Binding Ligands. J. Med Chem. 62, 8152\u20138163 (2019).","journal-title":"J. Med Chem."},{"key":"2176_CR428","doi-asserted-by":"crossref","unstructured":"Zhu, J. et al. Structure-based design, synthesis, and evaluation of Bcl-2\/Mcl-1 dual inhibitors. Arch. Pharm. 353, e2000005 (2020).","DOI":"10.1002\/ardp.202000005"},{"key":"2176_CR429","doi-asserted-by":"publisher","first-page":"101960","DOI":"10.1016\/j.xcrp.2024.101960","volume":"5","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Thalidomide derivatives degrade BCL-2 by reprogramming the binding surface of CRBN. Cell Rep. Phys. Sci. 5, 101960 (2024).","journal-title":"Cell Rep. Phys. Sci"},{"key":"2176_CR430","doi-asserted-by":"publisher","first-page":"14155","DOI":"10.1021\/jacs.3c05159","volume":"145","author":"M Chang","year":"2023","unstructured":"Chang, M. et al. Bioorthogonal PROTAC prodrugs enabled by on-target activation. J. Am. Chem. Soc. 145, 14155\u201314163 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"2176_CR431","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1517\/17425255.2011.579105","volume":"7","author":"PP Advani","year":"2011","unstructured":"Advani, P. P. et al. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. Expert Opin. Drug Metab. Toxicol. 7, 765\u2013774 (2011).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"2176_CR432","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.1200\/JCO.2009.22.5748","volume":"27","author":"S O\u2019Brien","year":"2009","unstructured":"O\u2019Brien, S. et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J. Clin. Oncol. 27, 5208\u20135212 (2009).","journal-title":"J. Clin. Oncol."},{"key":"2176_CR433","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45609-0","volume":"15","author":"EN Hoogenboezem","year":"2024","unstructured":"Hoogenboezem, E. N. et al. Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy. Nat. Commun. 15, 1581 (2024).","journal-title":"Nat. Commun."},{"key":"2176_CR434","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101\u2013124 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2176_CR435","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.413","volume":"5","author":"D Schmid","year":"2014","unstructured":"Schmid, D. et al. Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity. Cell Death Dis. 5, e1454 (2014).","journal-title":"Cell Death Dis."},{"key":"2176_CR436","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1182\/blood.2020008017","volume":"137","author":"N Bala Tannan","year":"2021","unstructured":"Bala Tannan, N. et al. Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition. Blood 137, 2057\u20132069 (2021).","journal-title":"Blood"},{"key":"2176_CR437","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2217\/nnm-2023-0132","volume":"18","author":"D Panwar","year":"2023","unstructured":"Panwar, D. et al. Hyaluronic acid-engineered Bcl-2 inhibitor nanocrystals for site-specific delivery to breast tumor cells. Nanomedicine 18, 1005\u20131023 (2023).","journal-title":"Nanomedicine"},{"key":"2176_CR438","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","volume":"4","author":"CM Patterson","year":"2021","unstructured":"Patterson, C. M. et al. Design and optimisation of dendrimer-conjugated Bcl-2\/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun. Biol. 4, 112 (2021).","journal-title":"Commun. Biol."},{"key":"2176_CR439","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41420-021-00505-0","volume":"7","author":"S Arulananda","year":"2021","unstructured":"Arulananda, S. et al. A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discov. 7, 122 (2021).","journal-title":"Cell Death Discov."},{"key":"2176_CR440","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.1182\/blood-2023-179168","volume":"142","author":"S Arslan","year":"2023","unstructured":"Arslan, S. et al. Safety and tolerability of AZD0466 as monotherapy for patients with advanced hematologic malignancies. results from a Phase I\/II Trial. Blood 142, 5907\u20135907 (2023).","journal-title":"Blood"},{"key":"2176_CR441","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1200\/JCO.2023.41.16_suppl.3027","volume":"41","author":"BA Carneiro","year":"2023","unstructured":"Carneiro, B. A. et al. Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed\/refractory solid tumors: Dose expansion results. J. Clin. Oncol. 41, 3027 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2176_CR442","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1200\/JCO.2021.39.15_suppl.3015","volume":"39","author":"AW Tolcher","year":"2021","unstructured":"Tolcher, A. W. et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed\/refractory solid tumors: Dose escalation results. J. Clin. Oncol. 39, 3015 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2176_CR443","doi-asserted-by":"publisher","first-page":"S759","DOI":"10.1016\/j.annonc.2023.09.2352","volume":"34","author":"JK Rotow","year":"2023","unstructured":"Rotow, J. K. et al. 1318MO First-in-human study of ABBV-637, an EGFR-targeting BCL-XL\u2013inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed\/refractory, EGFR-mutated non-small cell lung cancer (NSCLC). Ann. Oncol. 34, S759 (2023).","journal-title":"Ann. Oncol."},{"key":"2176_CR444","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.chembiol.2017.03.011","volume":"24","author":"X Niu","year":"2017","unstructured":"Niu, X. et al. A small-molecule inhibitor of Bax and Bak oligomerization prevents genotoxic cell death and promotes neuroprotection. Cell Chem. Biol. 24, 493\u2013506 e495 (2017).","journal-title":"Cell Chem. Biol."},{"key":"2176_CR445","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1523\/JNEUROSCI.2345-11.2012","volume":"32","author":"B D\u2019Orsi","year":"2012","unstructured":"D\u2019Orsi, B. et al. Calpains are downstream effectors of bax-dependent excitotoxic apoptosis. J. Neurosci. 32, 1847\u20131858 (2012).","journal-title":"J. Neurosci."},{"key":"2176_CR446","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41589-018-0223-0","volume":"15","author":"TP Garner","year":"2019","unstructured":"Garner, T. P. et al. Small-molecule allosteric inhibitors of BAX. Nat. Chem. Biol. 15, 322\u2013330 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"2176_CR447","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0006-8993(97)01202-X","volume":"780","author":"Y Kitamura","year":"1998","unstructured":"Kitamura, Y. et al. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer\u2019s disease. Brain Res. 780, 260\u2013269 (1998).","journal-title":"Brain Res."},{"key":"2176_CR448","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s41418-023-01153-w","volume":"30","author":"I Vitale","year":"2023","unstructured":"Vitale, I. et al. Apoptotic cell death in disease-Current understanding of the NCCD 2023. Cell Death Differ. 30, 1097\u20131154 (2023).","journal-title":"Cell Death Differ."},{"key":"2176_CR449","doi-asserted-by":"publisher","first-page":"7533","DOI":"10.1523\/JNEUROSCI.16-23-07533.1996","volume":"16","author":"E Paradis","year":"1996","unstructured":"Paradis, E. et al. Amyloid beta peptide of Alzheimer\u2019s disease downregulates Bcl-2 and upregulates bax expression in human neurons. J. Neurosci. 16, 7533\u20137539 (1996).","journal-title":"J. Neurosci."},{"key":"2176_CR450","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.43","volume":"3","author":"W Kudo","year":"2012","unstructured":"Kudo, W. et al. Inhibition of Bax protects neuronal cells from oligomeric Abeta neurotoxicity. Cell Death Dis. 3, e309 (2012).","journal-title":"Cell Death Dis."},{"key":"2176_CR451","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1021\/acs.jmedchem.0c02200","volume":"64","author":"JP Pogmore","year":"2021","unstructured":"Pogmore, J. P., Uehling, D. & Andrews, D. W. Pharmacological targeting of executioner proteins: controlling life and death. J. Med Chem. 64, 5276\u20135290 (2021).","journal-title":"J. Med Chem."},{"key":"2176_CR452","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1523\/JNEUROSCI.5620-07.2008","volume":"28","author":"TT Rohn","year":"2008","unstructured":"Rohn, T. T. et al. Lack of pathology in a triple transgenic mouse model of Alzheimer\u2019s disease after overexpression of the anti-apoptotic protein Bcl-2. J. Neurosci. 28, 3051\u20133059 (2008).","journal-title":"J. Neurosci."},{"key":"2176_CR453","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.nbd.2006.09.007","volume":"25","author":"R Karlnoski","year":"2007","unstructured":"Karlnoski, R. et al. Up-regulation of Bcl-2 in APP transgenic mice is associated with neuroprotection. Neurobiol. Dis. 25, 179\u2013188 (2007).","journal-title":"Neurobiol. Dis."},{"key":"2176_CR454","first-page":"48","volume":"1","author":"DK Kumasaka","year":"2009","unstructured":"Kumasaka, D. K., Galvan, V., Head, E. & Rohn, T. T. Caspase cleavage of the amyloid precursor protein is prevented after overexpression of bcl-2 in a triple transgenic mouse model of Alzheimer\u2019s disease. Int J. Physiol. Pathophysiol. Pharmacol. 1, 48\u201356 (2009).","journal-title":"Int J. Physiol. Pathophysiol. Pharmacol."},{"key":"2176_CR455","doi-asserted-by":"publisher","first-page":"a035212","DOI":"10.1101\/cshperspect.a035212","volume":"12","author":"S Schrank","year":"2020","unstructured":"Schrank, S., Barrington, N. & Stutzmann, G. E. Calcium-Handling Defects and Neurodegenerative Disease. Cold Spring Harb. Perspect. Biol 12, a035212 (2020).","journal-title":"Cold Spring Harb. Perspect. Biol"},{"key":"2176_CR456","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1002\/alz.13065","volume":"19","author":"EK Webber","year":"2023","unstructured":"Webber, E. K., Fivaz, M., Stutzmann, G. E. & Griffioen, G. Cytosolic calcium: Judge, jury and executioner of neurodegeneration in Alzheimer\u2019s disease and beyond. Alzheimers Dement. 19, 3701\u20133717 (2023).","journal-title":"Alzheimers Dement."},{"key":"2176_CR457","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2174\/1567205017666200528162046","volume":"17","author":"E Popugaeva","year":"2020","unstructured":"Popugaeva, E., Chernyuk, D. & Bezprozvanny, I. Reversal of calcium dysregulation as potential approach for treating Alzheimer\u2019s disease. Curr. Alzheimer Res. 17, 344\u2013354 (2020).","journal-title":"Curr. Alzheimer Res."},{"key":"2176_CR458","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1113\/JP286421","volume":"602","author":"GE Stutzmann","year":"2024","unstructured":"Stutzmann, G. E. & Soboloff, J. Channelling calcium signals to therapeutics. J. Physiol. 602, 1445\u20131447 (2024).","journal-title":"J. Physiol."},{"key":"2176_CR459","doi-asserted-by":"publisher","first-page":"150748","DOI":"10.1016\/j.bbrc.2024.150748","volume":"734","author":"R Dahl","year":"2024","unstructured":"Dahl, R. & Bezprozvanny, I. SERCA pump as a novel therapeutic target for treating neurodegenerative disorders. Biochem Biophys. Res Commun. 734, 150748 (2024).","journal-title":"Biochem Biophys. Res Commun."},{"key":"2176_CR460","doi-asserted-by":"publisher","first-page":"ra22","DOI":"10.1126\/scisignal.2000818","volume":"3","author":"KH Cheung","year":"2010","unstructured":"Cheung, K. H. et al. Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer\u2019s disease-linked presenilin mutants in human cells and mouse neurons. Sci. Signal. 3, ra22 (2010).","journal-title":"Sci. Signal."},{"key":"2176_CR461","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1089\/ars.2010.3421","volume":"14","author":"M Muller","year":"2011","unstructured":"Muller, M., Cheung, K. H. & Foskett, J. K. Enhanced ROS generation mediated by Alzheimer\u2019s disease presenilin regulation of InsP3R Ca2+ signaling. Antioxid. Redox Signal. 14, 1225\u20131235 (2011).","journal-title":"Antioxid. Redox Signal."},{"key":"2176_CR462","doi-asserted-by":"publisher","first-page":"6910","DOI":"10.1523\/JNEUROSCI.5441-13.2014","volume":"34","author":"D Shilling","year":"2014","unstructured":"Shilling, D. et al. Suppression of InsP3 receptor-mediated Ca2+ signaling alleviates mutant presenilin-linked familial Alzheimer\u2019s disease pathogenesis. J. Neurosci. 34, 6910\u20136923 (2014).","journal-title":"J. Neurosci."},{"key":"2176_CR463","doi-asserted-by":"publisher","first-page":"12128","DOI":"10.1523\/JNEUROSCI.2474-10.2010","volume":"30","author":"I Goussakov","year":"2010","unstructured":"Goussakov, I., Miller, M. B. & Stutzmann, G. E. NMDA-mediated Ca(2+) influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer\u2019s disease mice. J. Neurosci. 30, 12128\u201312137 (2010).","journal-title":"J. Neurosci."},{"key":"2176_CR464","doi-asserted-by":"publisher","first-page":"1001,e1001","DOI":"10.1016\/j.neurobiolaging.2011.03.011","volume":"33","author":"AM Bruno","year":"2012","unstructured":"Bruno, A. M. et al. Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer\u2019s disease. Neurobiol. Aging 33, 1001,e1001\u2013e1006 (2012).","journal-title":"Neurobiol. Aging"},{"key":"2176_CR465","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1750-1326-6-81","volume":"6","author":"X Chen","year":"2011","unstructured":"Chen, X. et al. Dantrolene is neuroprotective in Huntington\u2019s disease transgenic mouse model. Mol. Neurodegener. 6, 81 (2011).","journal-title":"Mol. Neurodegener."},{"key":"2176_CR466","doi-asserted-by":"publisher","first-page":"8341","DOI":"10.1523\/JNEUROSCI.0936-12.2012","volume":"32","author":"S Chakroborty","year":"2012","unstructured":"Chakroborty, S. et al. Early presynaptic and postsynaptic calcium signaling abnormalities mask underlying synaptic depression in presymptomatic Alzheimer\u2019s disease mice. J. Neurosci. 32, 8341\u20138353 (2012).","journal-title":"J. Neurosci."},{"key":"2176_CR467","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4161\/chan.27471","volume":"8","author":"J Liu","year":"2014","unstructured":"Liu, J. et al. The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease. Channels. 8, 230\u2013242 (2014).","journal-title":"Channels."},{"key":"2176_CR468","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1523\/JNEUROSCI.1820-22.2022","volume":"43","author":"H Zhang","year":"2023","unstructured":"Zhang, H., Knight, C., Chen, S. R. W. & Bezprozvanny, I. A gating mutation in Ryanodine Receptor Type 2 rescues phenotypes of Alzheimer\u2019s disease mouse models by upregulating neuronal autophagy. J. Neurosci. 43, 1441\u20131454 (2023).","journal-title":"J. Neurosci."},{"key":"2176_CR469","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1007\/s00018-019-03091-8","volume":"76","author":"H Ivanova","year":"2019","unstructured":"Ivanova, H. et al. Bcl-2 and IP(3) compete for the ligand-binding domain of IP(3)Rs modulating Ca(2+) signaling output. Cell Mol. Life Sci. 76, 3843\u20133859 (2019).","journal-title":"Cell Mol. Life Sci."},{"key":"2176_CR470","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ibneur.2023.02.005","volume":"14","author":"D Chernyuk","year":"2023","unstructured":"Chernyuk, D. et al. Neuroprotective properties of anti-apoptotic BCL-2 proteins in 5xFAD mouse model of Alzheimer\u2019s disease. IBRO Neurosci. Rep. 14, 273\u2013283 (2023).","journal-title":"IBRO Neurosci. Rep."},{"key":"2176_CR471","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1017\/S1461145713001314","volume":"17","author":"SS Tang","year":"2014","unstructured":"Tang, S. S. et al. Protective effect of pranlukast on Abeta(1)(-)(4)(2)-induced cognitive deficits associated with downregulation of cysteinyl leukotriene receptor 1. Int. J. Neuropsychopharmacol. 17, 581\u2013592 (2014).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"2176_CR472","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.neuropharm.2014.01.011","volume":"79","author":"J Lai","year":"2014","unstructured":"Lai, J. et al. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Abeta1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice. Neuropharmacology 79, 707\u2013714 (2014).","journal-title":"Neuropharmacology"},{"key":"2176_CR473","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.pbb.2014.07.006","volume":"124","author":"H Wang","year":"2014","unstructured":"Wang, H. et al. Pretreatment with antiasthmatic drug ibudilast ameliorates Abeta 1-42-induced memory impairment and neurotoxicity in mice. Pharm. Biochem Behav. 124, 373\u2013379 (2014).","journal-title":"Pharm. Biochem Behav."},{"key":"2176_CR474","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/mds.25462","volume":"28","author":"B Dehay","year":"2013","unstructured":"Dehay, B. et al. Lysosomal impairment in Parkinson\u2019s disease. Mov. Disord. 28, 725\u2013732 (2013).","journal-title":"Mov. Disord."},{"key":"2176_CR475","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/cdd.2009.214","volume":"17","author":"C Oberle","year":"2010","unstructured":"Oberle, C. et al. Lysosomal membrane permeabilization and cathepsin release is a Bax\/Bak-dependent, amplifying event of apoptosis in fibroblasts and monocytes. Cell Death Differ. 17, 1167\u20131178 (2010).","journal-title":"Cell Death Differ."},{"key":"2176_CR476","doi-asserted-by":"publisher","first-page":"e30543","DOI":"10.7554\/eLife.30543","volume":"6","author":"J Karch","year":"2017","unstructured":"Karch, J. et al. Autophagic cell death is dependent on lysosomal membrane permeability through Bax and Bak. Elife 6, e30543 (2017).","journal-title":"Elife"},{"key":"2176_CR477","doi-asserted-by":"publisher","first-page":"889","DOI":"10.4161\/auto.28286","volume":"10","author":"J Bove","year":"2014","unstructured":"Bove, J. et al. BAX channel activity mediates lysosomal disruption linked to Parkinson disease. Autophagy 10, 889\u2013900 (2014).","journal-title":"Autophagy"},{"key":"2176_CR478","first-page":"135","volume":"16","author":"S Przedborski","year":"2000","unstructured":"Przedborski, S. et al. The parkinsonian toxin MPTP: action and mechanism. Restor. Neurol. Neurosci. 16, 135\u2013142 (2000).","journal-title":"Restor. Neurol. Neurosci."},{"key":"2176_CR479","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1073\/pnas.051633998","volume":"98","author":"M Vila","year":"2001","unstructured":"Vila, M. et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease. Proc. Natl Acad. Sci. USA 98, 2837\u20132842 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR480","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.1073\/pnas.95.10.5789","volume":"95","author":"D Offen","year":"1998","unstructured":"Offen, D. et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proc. Natl Acad. Sci. USA 95, 5789\u20135794 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR481","doi-asserted-by":"publisher","first-page":"8145","DOI":"10.1523\/JNEUROSCI.18-20-08145.1998","volume":"18","author":"L Yang","year":"1998","unstructured":"Yang, L. et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J. Neurosci. 18, 8145\u20138152 (1998).","journal-title":"J. Neurosci."},{"key":"2176_CR482","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ana.410400307","volume":"40","author":"X Mu","year":"1996","unstructured":"Mu, X. et al. Altered expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. Ann. Neurol. 40, 379\u2013386 (1996).","journal-title":"Ann. Neurol."},{"key":"2176_CR483","doi-asserted-by":"publisher","first-page":"9119","DOI":"10.1523\/JNEUROSCI.20-24-09119.2000","volume":"20","author":"S Vukosavic","year":"2000","unstructured":"Vukosavic, S. et al. Delaying caspase activation by Bcl-2: A clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 20, 9119\u20139125 (2000).","journal-title":"J. Neurosci."},{"key":"2176_CR484","doi-asserted-by":"publisher","first-page":"8774","DOI":"10.1523\/JNEUROSCI.2315-06.2006","volume":"26","author":"TW Gould","year":"2006","unstructured":"Gould, T. W. et al. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J. Neurosci. 26, 8774\u20138786 (2006).","journal-title":"J. Neurosci."},{"key":"2176_CR485","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/sj.cdd.4402166","volume":"14","author":"C Hetz","year":"2007","unstructured":"Hetz, C. et al. The proapoptotic BCL-2 family member BIM mediates motoneuron loss in a model of amyotrophic lateral sclerosis. Cell Death Differ. 14, 1386\u20131389 (2007).","journal-title":"Cell Death Differ."},{"key":"2176_CR486","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1073\/pnas.88.19.8661","volume":"88","author":"A Strasser","year":"1991","unstructured":"Strasser, A. et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl Acad. Sci. USA 88, 8661\u20138665 (1991).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2176_CR487","first-page":"1580","volume":"34","author":"BL Liphaus","year":"2007","unstructured":"Liphaus, B. L., Kiss, M. H., Carrasco, S. & Goldenstein-Schainberg, C. Increased Fas and Bcl-2 expression on peripheral mononuclear cells from patients with active juvenile-onset systemic lupus erythematosus. J. Rheumatol. 34, 1580\u20131584 (2007).","journal-title":"J. Rheumatol."},{"key":"2176_CR488","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/art.1780371004","volume":"37","author":"M Aringer","year":"1994","unstructured":"Aringer, M. et al. High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum. 37, 1423\u20131430 (1994).","journal-title":"Arthritis Rheum."},{"key":"2176_CR489","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1006\/jaut.1994.1046","volume":"7","author":"PA Gatenby","year":"1994","unstructured":"Gatenby, P. A. & Irvine, M. The bcl-2 proto-oncogene is overexpressed in systemic lupus erythematosus. J. Autoimmun. 7, 623\u2013631 (1994).","journal-title":"J. Autoimmun."},{"key":"2176_CR490","doi-asserted-by":"publisher","first-page":"300060521101918","DOI":"10.1177\/03000605211019187","volume":"49","author":"W Wang","year":"2021","unstructured":"Wang, W., Wang, X., Yang, K. & Fan, Y. Association of BCL2 polymorphisms and the IL19 single nucleotide polymorphism rs2243188 with systemic lupus erythematosus. J. Int. Med. Res. 49, 3000605211019187 (2021).","journal-title":"J. Int. Med. Res."},{"key":"2176_CR491","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13075-023-03203-7","volume":"25","author":"K Kielbassa","year":"2023","unstructured":"Kielbassa, K. et al. Differential expression pattern of Bcl-2 family members in B and T cells in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther. 25, 225 (2023).","journal-title":"Arthritis Res. Ther."},{"key":"2176_CR492","doi-asserted-by":"publisher","first-page":"7482","DOI":"10.4049\/jimmunol.0802813","volume":"182","author":"PD Bardwell","year":"2009","unstructured":"Bardwell, P. D. et al. The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J. Immunol. 182, 7482\u20137489 (2009).","journal-title":"J. Immunol."},{"key":"2176_CR493","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40262-019-00818-5","volume":"59","author":"A Nader","year":"2020","unstructured":"Nader, A., Minocha, M. & Othman, A. A. Exposure-response analyses of the effects of venetoclax, a selective BCL-2 inhibitor, on B-Lymphocyte and total lymphocyte counts in women with systemic Lupus Erythematosus. Clin. Pharmacokinet. 59, 335\u2013347 (2020).","journal-title":"Clin. Pharmacokinet."},{"key":"2176_CR494","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s40262-017-0625-2","volume":"57","author":"M Minocha","year":"2018","unstructured":"Minocha, M., Zeng, J., Medema, J. K. & Othman, A. A. Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) inhibitor venetoclax in female subjects with systemic Lupus Erythematosus. Clin. Pharmacokinet. 57, 1185\u20131198 (2018).","journal-title":"Clin. Pharmacokinet."},{"key":"2176_CR495","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/0961203317719334","volume":"27","author":"P Lu","year":"2018","unstructured":"Lu, P. et al. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus. Lupus 27, 290\u2013302 (2018).","journal-title":"Lupus"},{"key":"2176_CR496","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/75068","volume":"6","author":"R Atreya","year":"2000","unstructured":"Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 6, 583\u2013588 (2000).","journal-title":"Nat. Med."},{"key":"2176_CR497","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.4049\/jimmunol.163.2.1081","volume":"163","author":"K Ina","year":"1999","unstructured":"Ina, K. et al. Resistance of Crohn\u2019s disease T cells to multiple apoptotic signals is associated with a Bcl-2\/Bax mucosal imbalance. J. Immunol. 163, 1081\u20131090 (1999).","journal-title":"J. Immunol."},{"key":"2176_CR498","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ibd\/izab166","volume":"28","author":"LA Johnson","year":"2022","unstructured":"Johnson, L. A. et al. Effect of ABT-263 on intestinal fibrosis in human myofibroblasts, human intestinal organoids, and the mouse Salmonella typhimurium Model. Inflamm. Bowel Dis. 28, 161\u2013175 (2022).","journal-title":"Inflamm. Bowel Dis."},{"key":"2176_CR499","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/ibd\/izy147","volume":"24","author":"B Weder","year":"2018","unstructured":"Weder, B. et al. BCL2 regulates differentiation of intestinal fibroblasts. Inflamm. Bowel Dis. 24, 1953\u20131966 (2018).","journal-title":"Inflamm. Bowel Dis."},{"key":"2176_CR500","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.tcb.2011.03.001","volume":"21","author":"EN Gurzov","year":"2011","unstructured":"Gurzov, E. N. & Eizirik, D. L. Bcl-2 proteins in diabetes: mitochondrial pathways of beta-cell death and dysfunction. Trends Cell Biol. 21, 424\u2013431 (2011).","journal-title":"Trends Cell Biol."},{"key":"2176_CR501","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.cmet.2019.01.021","volume":"29","author":"PJ Thompson","year":"2019","unstructured":"Thompson, P. J. et al. Targeted elimination of senescent beta cells prevents Type 1 Diabetes. Cell Metab. 29, 1045\u20131060.e1010 (2019).","journal-title":"Cell Metab."},{"key":"2176_CR502","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nm.4010","volume":"22","author":"J Chang","year":"2016","unstructured":"Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78\u201383 (2016).","journal-title":"Nat. Med."},{"key":"2176_CR503","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0014-4827(61)90192-6","volume":"25","author":"L Hayflick","year":"1961","unstructured":"Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585\u2013621 (1961).","journal-title":"Exp. Cell Res."},{"key":"2176_CR504","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.mad.2008.04.001","volume":"129","author":"JC Jeyapalan","year":"2008","unstructured":"Jeyapalan, J. C. & Sedivy, J. M. Cellular senescence and organismal aging. Mech. Ageing Dev. 129, 467\u2013474 (2008).","journal-title":"Mech. Ageing Dev."},{"key":"2176_CR505","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/S0962-8924(01)82148-6","volume":"11","author":"J Campisi","year":"2001","unstructured":"Campisi, J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 11, S27\u2013S31 (2001).","journal-title":"Trends Cell Biol."},{"key":"2176_CR506","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","volume":"179","author":"V Gorgoulis","year":"2019","unstructured":"Gorgoulis, V. et al. Cellular senescence: defining a path forward. Cell 179, 813\u2013827 (2019).","journal-title":"Cell"},{"key":"2176_CR507","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","volume":"75","author":"J Campisi","year":"2013","unstructured":"Campisi, J. Aging, cellular senescence, and cancer. Annu Rev. Physiol. 75, 685\u2013705 (2013).","journal-title":"Annu Rev. Physiol."},{"key":"2176_CR508","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/joim.13141","volume":"288","author":"J Kirkland","year":"2020","unstructured":"Kirkland, J. & Tchkonia, T. Senolytic drugs: from discovery to translation. J. Intern. Med. 288, 518\u2013536 (2020).","journal-title":"J. Intern. Med."},{"key":"2176_CR509","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1042\/BST20231066","volume":"52","author":"V Dhokia","year":"2024","unstructured":"Dhokia, V. et al. A second generation of senotherapies: the development of targeted senolytics, senoblockers and senoreversers for healthy ageing. Biochem. Soc. Trans. 52, 1661\u20131671 (2024).","journal-title":"Biochem. Soc. Trans."},{"key":"2176_CR510","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41591-018-0092-9","volume":"24","author":"M Xu","year":"2018","unstructured":"Xu, M. et al. Senolytics improve physical function and increase lifespan in old age. Nat. Med. 24, 1246\u20131256 (2018).","journal-title":"Nat. Med."},{"key":"2176_CR511","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","volume":"47","author":"LJ Hickson","year":"2019","unstructured":"Hickson, L. J. et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine 47, 446\u2013456 (2019).","journal-title":"EBioMedicine"},{"key":"2176_CR512","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.4155\/fmc-2018-0366","volume":"11","author":"A Anantram","year":"2019","unstructured":"Anantram, A. & Degani, M. Targeting cancer\u2019s Achilles\u2019 heel: role of BCL-2 inhibitors in cellular senescence and apoptosis. Future Med. Chem. 11, 2287\u20132312 (2019).","journal-title":"Future Med. Chem."},{"key":"2176_CR513","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11190","volume":"7","author":"R Yosef","year":"2016","unstructured":"Yosef, R. et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun. 7, 11190 (2016).","journal-title":"Nat. Commun."},{"key":"2176_CR514","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41586-023-06621-4","volume":"622","author":"S Victorelli","year":"2023","unstructured":"Victorelli, S. et al. Apoptotic stress causes mtDNA release during senescence and drives the SASP. Nature 622, 627\u2013636 (2023).","journal-title":"Nature"},{"key":"2176_CR515","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3389\/fcell.2020.00354","volume":"8","author":"AK Sharma","year":"2020","unstructured":"Sharma, A. K. et al. The senolytic drug navitoclax (ABT-263) causes trabecular bone loss and impaired osteoprogenitor function in aged mice. Front Cell Dev. Biol. 8, 354 (2020).","journal-title":"Front Cell Dev. Biol."},{"key":"2176_CR516","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/hep.29464","volume":"67","author":"A Moncsek","year":"2018","unstructured":"Moncsek, A. et al. Targeting senescent cholangiocytes and activated fibroblasts with B\u2010cell lymphoma\u2010extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2\u2212\/\u2212) mice. Hepatology 67, 247\u2013259 (2018).","journal-title":"Hepatology"},{"key":"2176_CR517","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1038\/s41591-023-02543-w","volume":"29","author":"MM Gonzales","year":"2023","unstructured":"Gonzales, M. M. et al. Senolytic therapy in mild Alzheimer\u2019s disease: a phase 1 feasibility trial. Nat. Med. 29, 2481\u20132488 (2023).","journal-title":"Nat. Med."},{"key":"2176_CR518","doi-asserted-by":"publisher","first-page":"10556","DOI":"10.1002\/anie.201204663","volume":"51","author":"A Agostini","year":"2012","unstructured":"Agostini, A. et al. Targeted cargo delivery in senescent cells using capped mesoporous silica nanoparticles. Angew. Chem. Int Ed. 51, 10556\u201310560 (2012).","journal-title":"Angew. Chem. Int Ed."},{"key":"2176_CR519","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809355","volume":"10","author":"D Mu\u00f1oz\u2010Esp\u00edn","year":"2018","unstructured":"Mu\u00f1oz\u2010Esp\u00edn, D. et al. A versatile drug delivery system targeting senescent cells. EMBO Mol. Med. 10, e9355 (2018).","journal-title":"EMBO Mol. Med."},{"key":"2176_CR520","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"2176_CR521","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1182\/blood-2023-180386","volume":"142","author":"IS Tiong","year":"2023","unstructured":"Tiong, I. S. et al. BAX mutated clonal hematopoiesis arises following treatment with the BCL2 inhibitor class of therapeutics across a range of hematological and non-hematological neoplasms. Blood 142, 2688\u20132688 (2023).","journal-title":"Blood"},{"key":"2176_CR522","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","volume":"34","author":"R Bisaillon","year":"2020","unstructured":"Bisaillon, R. et al. Genetic characterization of ABT-199 sensitivity in human AML. Leukemia 34, 63\u201374 (2020).","journal-title":"Leukemia"},{"key":"2176_CR523","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat. Cancer 1, 826\u2013839 (2020).","journal-title":"Nat. Cancer"},{"key":"2176_CR524","doi-asserted-by":"publisher","first-page":"113539","DOI":"10.1016\/j.ejmech.2021.113539","volume":"220","author":"X Li","year":"2021","unstructured":"Li, X., Dou, J., You, Q. & Jiang, Z. Inhibitors of BCL2A1\/Bfl-1 protein: Potential stock in cancer therapy. Eur. J. Med. Chem. 220, 113539 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"2176_CR525","doi-asserted-by":"crossref","unstructured":"Araujo, A. D. et al. Bicyclic helical peptides as dual inhibitors selective for Bcl2A1 and Mcl-1 proteins. J. Med. Chem. 61, 2962\u20132972 (2018).","DOI":"10.1021\/acs.jmedchem.8b00010"},{"key":"2176_CR526","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1021\/acsmedchemlett.4c00113","volume":"15","author":"SCC Lucas","year":"2024","unstructured":"Lucas, S. C. C. et al. Identification and Evaluation of Reversible Covalent Binders to Cys55 of Bfl-1 from a DNA-Encoded Chemical Library Screen. ACS Med Chem. Lett. 15, 791\u2013797 (2024).","journal-title":"ACS Med Chem. Lett."},{"key":"2176_CR527","doi-asserted-by":"publisher","first-page":"10795","DOI":"10.1021\/acs.jmedchem.4c00291","volume":"67","author":"J Lou","year":"2024","unstructured":"Lou, J. et al. Discovery of a covalent inhibitor that overcame resistance to Venetoclax in AML cells overexpressing BFL-1. J. Med. Chem. 67, 10795\u201310830 (2024).","journal-title":"J. Med. Chem."},{"key":"2176_CR528","doi-asserted-by":"publisher","first-page":"16455","DOI":"10.1021\/acs.jmedchem.4c01288","volume":"67","author":"SCC Lucas","year":"2024","unstructured":"Lucas, S. C. C. et al. Structure-based optimization of a series of covalent, cell active Bfl-1 inhibitors. J. Med. Chem. 67, 16455\u201316479 (2024).","journal-title":"J. Med. Chem."},{"key":"2176_CR529","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"T Nechiporuk","year":"2019","unstructured":"Nechiporuk, T. et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 9, 910\u2013925 (2019).","journal-title":"Cancer Discov."},{"key":"2176_CR530","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood.2020010167","volume":"137","author":"R Thijssen","year":"2021","unstructured":"Thijssen, R. et al. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood 137, 2721\u20132735 (2021).","journal-title":"Blood"},{"key":"2176_CR531","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea, D. A. et al. Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with Venetoclax and Azacitidine. Clin. Cancer Res. 28, 5272\u20135279 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2176_CR532","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2024.04.004","volume":"42","author":"ST Diepstraten","year":"2024","unstructured":"Diepstraten, S. T. et al. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. Cancer Cell. 42, 850\u2013868.e859 (2024).","journal-title":"Cancer Cell."},{"key":"2176_CR533","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.canlet.2020.02.041","volume":"482","author":"S Kehr","year":"2020","unstructured":"Kehr, S. et al. Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-X(L) and MCL-1 leads to rapid induction of intrinsic apoptosis. Cancer Lett. 482, 19\u201332 (2020).","journal-title":"Cancer Lett."},{"key":"2176_CR534","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado, J. et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin. Cancer Res. 26, 922\u2013934 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2176_CR535","doi-asserted-by":"publisher","first-page":"15564","DOI":"10.1021\/acs.jmedchem.0c01754","volume":"63","author":"B Barlaam","year":"2020","unstructured":"Barlaam, B. et al. Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies. J. Med. Chem. 63, 15564\u201315590 (2020).","journal-title":"J. Med. Chem."},{"key":"2176_CR536","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMoa2401532","volume":"390","author":"C Melani","year":"2024","unstructured":"Melani, C. et al. Combination targeted therapy in relapsed diffuse large B-cell lymphoma. N. Engl. J. Med. 390, 2143\u20132155 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2176_CR537","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/bjh.12219","volume":"160","author":"MJS Dyer","year":"2013","unstructured":"Dyer, M. J. S. et al. Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls. Br. J. Haematol. 160, 725\u2013733 (2013).","journal-title":"Br. J. Haematol."},{"key":"2176_CR538","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMe2405437","volume":"390","author":"JS Goldstein","year":"2024","unstructured":"Goldstein, J. S. & Alizadeh, A. A. ViPOR\u2019s venom - rationally targeting DLBCL with precision. N. Engl. J. Med. 390, 2209\u20132211 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2176_CR539","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07551-w","volume":"9","author":"AE Tron","year":"2018","unstructured":"Tron, A. E. et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat. Commun. 9, 5341 (2018).","journal-title":"Nat. Commun."},{"key":"2176_CR540","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15838-0","volume":"11","author":"Y He","year":"2020","unstructured":"He, Y. et al. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat. Commun. 11, 1996 (2020).","journal-title":"Nat. Commun."},{"key":"2176_CR541","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn, I. et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE biopharma collaborative in cBioPortal. Cancer Res. 83, 3861\u20133867 (2023).","journal-title":"Cancer Res."},{"key":"2176_CR542","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"2176_CR543","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"2176_CR544","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/nm0817-1004c","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 1004 (2017).","journal-title":"Nat. Med."},{"key":"2176_CR545","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat. Genet. 52, 1219\u20131226 (2020).","journal-title":"Nat. Genet."},{"key":"2176_CR546","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31780-9","volume":"13","author":"L Wu","year":"2022","unstructured":"Wu, L. et al. Landscape of somatic alterations in large-scale solid tumors from an Asian population. Nat. Commun. 13, 4264 (2022).","journal-title":"Nat. Commun."},{"key":"2176_CR547","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","volume":"185","author":"B Nguyen","year":"2022","unstructured":"Nguyen, B. et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185, 563\u2013575.e511 (2022).","journal-title":"Cell"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02176-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02176-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02176-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T20:21:41Z","timestamp":1742502101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02176-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":547,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2176"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02176-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MJSD has received research funding from LOXO and Beigene and financial assistance with meeting attendance from Beigene. GB is involved in a fee-for-service agreement with ReMynd. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}